Cycloalkylcarboxylic acid derivatives as inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof

Abstract

Provided herein are compounds of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y 1 , Y 2 , X 1 , X 2 , X 3 , Q 1 , and R a is as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting GYS1 and treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof. [Formula 1] JPEG2025532594000158.jpg7269

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 406,682, filed September 14, 2022, the entire contents of which are incorporated herein by reference for all purposes. [Background technology]

[0002] Pathological accumulation of glycogen is a hallmark of several serious and chronic human diseases. For some of these disorders, the cellular etiology driving this abnormal accumulation has a clear genetic basis; for others, the mechanical drivers are more complex. Nevertheless, elevated glycogen levels result in altered cellular homeostasis and impaired tissue function over time. The rate-limiting enzyme in the glycogen synthesis pathway is the protein glycogen synthase (GYS). In humans, there are two isoforms: GYS1 and GYS2. The former is ubiquitously expressed but highly abundant in muscle cells, while the latter is expressed exclusively in the liver. Glycogen synthesis ultimately begins with the transport of glucose into cells via the GLUT family of transporters. The conversion of glucose to glycogen follows a well-characterized biochemical pathway, leading to the covalent attachment of glucose molecules via α1,4-glycosidic bonds to long, branched structures by GYS. Glycogen's final globular structure results from the action of glycogen branching enzyme (GBE), which introduces α1,6-linked branch points along the chain. This biochemical chain results in the production of an energy-dense, highly soluble molecule that can be stored in the cellular cytosol for rapid catabolism to glucose energy as needed. An imbalance in the equilibrium of either glycogen synthesis or glycogen degradation can result in abnormal accumulation of cellular glycogen stores. It has long been hypothesized that substrate-reducing therapies targeting inhibition of glycogen synthase could be an effective treatment for disorders of glycogen storage.Indeed, substrate reduction therapeutics have been highly successful in modifying the disease course in patients with other storage disorders, including Gaucher disease and Fabry disease (Platt FM, Butters TD. Substrate Reduction Therapy. Lysosomal Storage Disorders, Springer US chapter 11, pp. 153-168, 2007; Shemesh E, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database of Systematic Reviews, Issue 3, 2015). The objective of the present invention is to inhibit glycogen synthase enzyme activity, resulting in a reduction in tissue glycogen stores, with therapeutic benefit to patients suffering from the consequences of abnormal cellular glycogen accumulation.

[0003] Pompe disease is a rare genetic disorder caused by a pathological accumulation of cellular glycogen due to loss-of-function (LOF) mutations in the lysosomal enzyme α-glucosidase (GAA). GAA degrades lysosomal glycogen, and in its absence, glycogen accumulates in lysosomes. This triggers a disease cascade that begins with lysosomal and autophagosome dysfunction, ultimately leading to cell death and muscle atrophy over time (Raben N, et al. Autophagy and mitochondria in Pompe Disease: nothing is so new as what has long been forgotten. American Journal of Medical Genetics, vol. 160, 2012; van der Ploeg AT and Reuser AJJ, Pompe's Disease. Lancet vol. 372, 2008). In humans, the clinical manifestations of the disease range in severity and occur at a prevalence of 1 in 40,000 births (Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules, vol. 10, 2020). Infantile-onset patients are born with cellular pathology and rapidly develop severe disorders, including myopathy, cardiac defects, organ enlargement, and hypotension, which, if left untreated, can ultimately claim the child's life within a year. Late-onset children may develop cardiac enlargement but are consistently characterized by progressive loss of motor function, skeletal muscle degeneration, and eventual respiratory failure, leading to early death. Late-onset adult Pompe patients exhibit normal cardiac function but develop progressive muscle weakness and respiratory weakness, followed by respiratory failure. The current standard of care for Pompe patients is enzyme replacement therapy (ERT) with recombinant human GAA.Although ERT treatment has been successful in slowing disease progression, there remains an incredible unmet need in the majority of patients (Schoser B, et al. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurology, vol. 17, 2017). For over a decade, substrate reduction therapies targeting GYS1 have been hypothesized to be beneficial in the treatment of Pompe disease. Indeed, three separate preclinical studies have demonstrated that genetic LOF of GYS1 in Pompe disease mouse models effectively reduces tissue glycogen and improves disease outcomes in mice (Douillard-Guilloux G, et al. Modulation of glycogen synthesis by RNA interference: toward a new therapeutic approach for glycogenosis type II. Human Molecular Genetics, vol. 17, no. 24, 2008; Douillard-Guilloux G, et al. Restoration of muscle function by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Human Molecular Genetics, vol. 19, no. 4, 2010; Clayton NP, et al. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease. Molecular Therapy - Nucleic Acids, vol. 3, 2014). Small molecule GYS1 inhibitors may be used to address the current unmet needs of Pompe patients, either as monotherapy or in combination with standard of care ERT.

[0004] Pompe disease is only one of more than a dozen diseases caused by inborn errors of metabolism that result in abnormal accumulation of glycogen in various tissues of the body. While specific dietary treatments effectively manage some glycogen storage diseases (GSDs), for others, there are no clinically approved therapeutic interventions to alter the disease course. Therefore, inhibiting glycogen synthesis and the concomitant reduction of tissue glycogen levels may be a viable treatment option for these patients. Cori's disease, GSD III, is caused by mutations in glycogen debranching enzyme (GDE), which leads to pathological glycogen accumulation in the heart, skeletal muscle, and liver (Kishnani P, et al. Glycogen storage disease type III diagnosis and management guidelines. Genetics in Medicine, vol. 12, no. 7, 2010). While dietary management can be effective in ameliorating disease symptoms, there is currently no treatment to prevent progressive myopathy in GSD III. Adult polyglucosan body disease (APBD) is an adult-onset disorder caused by loss of glycogen branching enzyme (GBE1) activity. GBE deficiency leads to the accumulation of long chains of unbranched glycogen that precipitate in the cytosol, generating polyglucosan bodies, ultimately inducing neurological deficits in both the central and peripheral nervous systems. Genetic deletion of GYS1 in an APBD mouse model rescued the deleterious accumulation of glycogen, improved lifespan, and neuromuscular function (Chown EE, et al. GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease. Annals of Clinical and Translational Neurology, vol. 7, no. 11, 2020). Lafora disease (LD) is a highly debilitating early-onset epilepsy disorder similarly characterized by the accumulation of polyglucason bodies.Genetic crossing of the LD mouse model with GYS1 knockout (KO) mice resulted in rescue of the disease phenotype (Pedersen B, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Annals of Neurology, vol. 74, no. 2, 2013; Varea O, et al. Suppression of glycogen synthesis as a treatment for Lafora disease: establishing the window of opportunity. Neurobiology of Disease, 2020).

[0005] Recently, the dependence of clear cell carcinoma on high levels of glycogen has emerged as a novel therapeutic target. Ewing sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma of the breast (GRCC), acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC) are all examples of cancers histopathologically defined by abnormally high levels of PAS+ cellular glycogen. Increased GYS1 transcript levels have been significantly correlated with poor disease outcomes in NSCLC (Giatromanolaki A, et al. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Experimental Lung Research, vol. 43, no. 4-5, 2017) and AML (Falantes JF, et al. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia, vol. 15, no. 4, 2015). Lentiviral knockdown of GYS1 in cultured myeloid leukemia cells strongly inhibited cancer cell proliferation in vitro and tumor formation in vivo (Bhanot H, et al. Pathological glycogenesis through glycogen synthase I and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, vol. 29, no. 7, 2015).Genetic knockdown of GYS1 in a ccRCC cell model both inhibits tumor growth in vivo and increases the synthetic lethality of sunitinib (Chen S, et al. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-kB pathway in clear cell renal carcinoma. Theranostics, vol. 10, no. 20, 2020).

[0006] The reduction in GYS1 enzyme activity and reduction in cellular glycogen stores in preclinical models of Pompe disease, APBD, LD, AML, ccRCC, and NSCLC all provide strong evidence of the potential therapeutic benefit of inhibiting glycogen synthesis. The objective of the present invention is to inhibit glycogen synthase activity, resulting in a reduction in tissue glycogen stores, which will provide therapeutic benefit to patients suffering from the consequences of accumulated cellular glycogen. Summary of the Invention

[0007] As used herein, in one aspect, there is provided a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is 0 or 1, n is 0, 1, or 2, and m+n is an integer of 1 to 2; Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 But H, C 1~6Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; Q 1 but, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; (ii) C 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl, and R ais H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0008] As used herein, in one aspect, there is provided a compound of formula (IA): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , Y 1 , Y 2 , and R a is as defined elsewhere herein.

[0009] As used herein, in one aspect, there is provided a compound of formula (IB): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, X 1 , X 2 , X 3 , Y 1 , Y 2 , and R a is as defined elsewhere herein.

[0010] As used herein, in one aspect, there is provided a compound of formula (IC): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, X 1 , X 2 , X 3 , Y 1 , Y 2 , Ra and Ring A is as defined elsewhere herein.

[0011] As used herein, in one aspect, there is provided a compound of formula (ID): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, X 1 , X 2 , X 3 , Y 1 , Y 2 , R a and Ring A is as defined elsewhere herein.

[0012] In one aspect, the formula (IE): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n, X 1 , X 2 , X 3 , Y 1 , Y 2 , R a and Q 1 is as defined elsewhere herein.

[0013] In one embodiment, the formula (IF): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n, X 1 , X 2 , X 3 , Y 1 , Y 2 , R a and Q 1 is as defined elsewhere herein.

[0014] As used herein, in one aspect, there is provided a compound of formula (IG): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 , X 2 , X 3 , Y 1 , Y 2 , R a and Q 1 is as defined elsewhere herein.

[0015] As used herein, in one aspect, there is provided a compound of formula (IH): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 , X 2 , X 3 , Y 1 , Y 2 , R a and Q 1 is as defined elsewhere herein.

[0016] Provided herein, in one aspect, is a pharmaceutical composition comprising: (i) a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (ii) one or more pharmaceutically acceptable excipients.

[0017] Provided herein, in one aspect, is a method for modulating GYS1 in a cell, the method comprising exposing the cell to (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0018] Provided herein, in one aspect, is a method of inhibiting GYS1 in a cell, the method comprising exposing the cell to (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0019] Provided herein in one aspect is a method of reducing tissue glycogen stores in an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0020] Provided herein, in one aspect, is a method for modulating GYS1 in the cells of an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0021] Provided herein, in one aspect, is a method of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0022] Provided herein, in one aspect, is a method of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0023] In one aspect, provided herein is a kit comprising: (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

[0024] In one aspect, provided herein is a kit comprising: (i) a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or a pharmaceutical composition comprising a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing and one or more pharmaceutically acceptable excipients; and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

[0025]

[0013] Provided herein in some aspects are methods for preparing a compound of formula (I), or any embodiment or variation thereof, e.g., a compound of formula (I), (IA), (I-A1), (I-A2), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (I-B5), (IC), (ID), (IE), (I-E1), (I-E2), (IF), (I-F1), (IG), (I-G1), (I-G2), (I-G3), (I-G4), (IH), (I-H1), (I-H2), (I-H3), (I-H4), or (I-H5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. [Brief explanation of the drawings]

[0026] [Figure 1]Figure 1 shows the pathway by which PPP1R3A loss of function (LoF) leads to reduced muscle glycogen. [Figure 2A] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTVs) and left ventricular ejection fraction (LVEF) (%) and left ventricular wall thickness (mm) in UK Biobank. [Figure 2B] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTVs) and left ventricular ejection fraction (LVEF) (%) and left ventricular wall thickness (mm) in UK Biobank. [Figure 2C] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTV) and exercise power (watts), and maximum heart rate (HR) exercise (bpm) in UK Biobank. [Figure 2D] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTV) and exercise power (watts), and maximum heart rate (HR) exercise (bpm) in UK Biobank. [Figure 2E] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTVs) and PQ interval (ms) and QRS duration (ms) in UK Biobank. [Figure 2F] Association between PPP1R3A protein-truncating variants (PTVs) and PQ interval (ms) and QRS duration (ms) in UK Biobank [Figure 2G] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTVs) and QT interval (ms) and serum glucose (mmol / L) in UK Biobank. [Figure 2H] Figure 1 shows the association between PPP1R3A protein-truncating variants (PTVs) and QT interval (ms) and serum glucose (mmol / L) in UK Biobank. DETAILED DESCRIPTION OF THE INVENTION

[0027] "Individual" refers to mammals, including humans and non-human mammals. Examples of individuals include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, individual refers to a human.

[0028] As used herein, "about" in reference to a parameter or value includes and describes the parameter or value itself. For example, "about X" includes and describes X itself.

[0029] As used herein, an "at risk" individual is an individual at risk of developing a disease or condition. An "at risk" individual may or may not have a detectable disease or condition, and may or may not exhibit detectable disease prior to the treatment methods described herein. "At risk" means that an individual has one or more so-called risk factors, which are measurable parameters that correlate with the development of a disease or condition and are known in the art. Individuals who have one or more of these risk factors have a higher likelihood of developing a disease or condition than individuals who do not have these risk factors.

[0030] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired results may include one or more of the following: reducing one or more symptoms resulting from a disease or condition; reducing the severity of a disease or condition; delaying or preventing the onset of one or more symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or slowing the worsening or progression of a disease or condition); and alleviating the disease, such as by causing regression of clinical symptoms (e.g., ameliorating a disease state, enhancing the effect of another drug, slowing the progression of a disease, improving quality of life, and / or prolonging survival).

[0031] As used herein, "delaying the onset of a disease or condition" means to postpone, inhibit, slow, decelerate, stabilize, and / or postpone the onset of the disease or condition. This delay can be of varying lengths of time, depending on the disease being treated and / or the medical history of the individual. As will be apparent to one of skill in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition.

[0032] As used herein, the term "therapeutically effective amount" or "effective amount" refers to a compound of the present disclosure or a pharmaceutical salt thereof sufficient to provide treatment when administered to an individual. As understood in the art, an effective amount may be one or more administrations, e.g., a single administration or multiple administrations may be required to achieve a desired therapeutic endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents; a single agent may be considered to be administered in an effective amount if, in conjunction with one or more other agents, a desired or beneficial result may be obtained or achieved.

[0033] As used herein, "unit dosage form" refers to physically discrete units suitable as unit dosages, each containing a predetermined amount of active ingredient or compound, which may be in a pharmaceutically acceptable carrier.

[0034] As used herein, "pharmaceutically acceptable" means a substance that is not biologically or otherwise undesirable, e.g., the substance can be incorporated into a pharmaceutical composition administered to an individual without causing significant undesired biological effects.

[0035] The term "alkyl," as used herein, refers to an unbranched or branched monovalent saturated hydrocarbon chain. As used herein, alkyl refers to an alkyl group having 1 to 20 carbons (i.e., C 1~20 alkyl), 1 to 16 carbons (i.e., C 1~16 alkyl), 1 to 12 carbons (i.e., C 1~12 alkyl), 1 to 10 carbons (i.e., C 1~10alkyl), 1 to 8 carbons (i.e., C 1~8 alkyl), 1 to 6 carbons (i.e., C 1~6 alkyl), 1 to 4 carbons (i.e., C 1~4 alkyl), or 1 to 3 carbons (i.e., C 1~3 alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms are encompassed (e.g., "butyl" includes n-butyl, sec-butyl, isobutyl, and tert-butyl, and "propyl" includes n-propyl and isopropyl). Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group, such as a divalent "alkyl" group, may be referred to as an "alkylene."

[0036] As used herein, the term "alkenyl" refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon double bond. As used herein, alkenyl refers to a hydrocarbon chain having 2 to 20 carbons (i.e., C 2~20 alkenyl), 2 to 16 carbons (i.e., C 2~16 alkenyl), 2 to 12 carbons (i.e., C 2~12 alkenyl), 2 to 10 carbons (i.e., C 2~10 alkenyl), 2 to 8 carbons (i.e., C 2~8 alkenyl), 2 to 6 carbons (i.e., C 2~6 alkenyl), 2 to 4 carbons (i.e., C 2~4 alkenyl), or 2-3 carbons (i.e., C 2~3alkenyl). Examples of alkenyl include, but are not limited to, ethenyl, prop-1-enyl, prop-2-enyl-1,2-butadienyl, and 1,3-butadienyl. When an alkenyl residue having a specific number of carbon atoms is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms can be encompassed (e.g., "propenyl" includes prop-1-enyl and prop-2-enyl). Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group such as a divalent "alkenyl" group can be referred to as "alkenylene."

[0037] As used herein, the term "alkynyl" refers to a branched or unbranched monovalent hydrocarbon chain containing at least one carbon-carbon triple bond. As used herein, alkynyl refers to a hydrocarbon chain having 2 to 20 carbons (i.e., C 2~20 alkynyl), 2 to 16 carbons (i.e., C 2~16 alkynyl), 2 to 12 carbons (i.e., C 2~12 alkynyl), 2 to 10 carbons (i.e., C 2~10 alkynyl), 2 to 8 carbons (i.e., C 2~8 alkynyl), 2 to 6 carbons (i.e., C 2~6 alkynyl), 2 to 4 carbons (i.e., C 2~4 alkynyl), or 2-3 carbons (i.e., C 2~3 alkynyl). Examples of alkynyl include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, and but-3-ynyl. When an alkynyl residue having a specific number of carbons is named by a chemical name or molecular formula, all positional isomers having that number of carbon atoms can be included (e.g., "propynyl" includes prop-1-ynyl and prop-2-ynyl). Certain commonly used alternative names may be used and will be understood by those skilled in the art. For example, a divalent group such as a divalent "alkynyl" group can be referred to as an "alkynylene."

[0038] The term "alkoxy" as used herein refers to an -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0039] The term "aryl," as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term "aryl" encompasses monocyclic and polycyclic fused ring moieties. As used herein, aryl refers to, for example, a ring of 6 to 20 ring carbon atoms (i.e., C 6~20 aryl), 6 to 16 ring carbon atoms (i.e., C 6~16 aryl), 6 to 12 ring carbon atoms (i.e., C 6~12 aryl), or 6 to 10 ring carbon atoms (i.e., C 6~10 Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.

[0040] The term "cycloalkyl," as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term "cycloalkyl" encompasses monocyclic and polycyclic ring moieties, which may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, where the ring moiety contains at least one cyclic double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety containing at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, cycloalkyl refers to, for example, a ring having 3 to 20 ring carbon atoms (i.e., C 3~20 cycloalkyl), 3 to 16 ring carbon atoms (i.e., C 3~16 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3~12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3~10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3~8cycloalkyl), 3 to 6 ring carbon atoms (i.e., C 3~6 cycloalkyl), or 3 to 5 ring carbon atoms (i.e., C 3~5 Cycloalkyl includes rings containing cycloalkyl groups. Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Furthermore, cycloalkyl also includes spirocycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl.

[0041] The term "halo," as used herein, refers to those atoms occupying Group VIIA of the periodic table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo).

[0042] The term "heteroaryl," as used herein, refers to an aromatic (fully unsaturated) ring moiety containing one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heteroaryl" includes both monocyclic and polycyclic fused ring moieties. As used herein, heteroaryl includes, for example, 5 to 20 ring atoms (i.e., 5-20-membered heteroaryl), 5 to 16 ring atoms (i.e., 5-16-membered heteroaryl), 5 to 12 ring atoms (i.e., 5-12-membered heteroaryl), 5 to 10 ring atoms (i.e., 5-10-membered heteroaryl), 5 to 8 ring atoms (i.e., 5-8-membered heteroaryl), or 5 to 6 ring atoms (i.e., 5-6-membered heteroaryl). Any monocyclic or polycyclic aromatic ring moiety containing one or more ring heteroatoms is considered heteroaryl, regardless of the point of attachment to the remainder of the molecule (i.e., the heteroaryl moiety can be attached to the remainder of the molecule through any ring carbon or any ring heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, Including, but not limited to, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, and triazinyl.Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, and the heteroaryl may be attached via either ring of the fused system.

[0043] The term "heterocyclyl," as used herein, refers to a saturated or partially unsaturated cyclic moiety containing one or more ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heterocyclyl" includes both monocyclic and polycyclic ring moieties, which may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic aromatic ring moiety containing at least one ring heteroatom is considered to be heterocyclyl, regardless of the point of attachment to the rest of the molecule (i.e., the heterocyclyl moiety can be attached to the rest of the molecule through any ring carbon or any ring heteroatom of the heterocyclyl moiety). Furthermore, the term heterocyclyl is intended to encompass any polycyclic ring moiety containing at least one ring heteroatom, provided that the polycyclic ring moiety contains at least one non-aromatic ring, regardless of the point of attachment to the rest of the molecule. As used herein, heterocyclyl includes, for example, 3 to 20 ring atoms (i.e., 3-20-membered heterocyclyl), 3 to 16 ring atoms (i.e., 3-16-membered heterocyclyl), 3 to 12 ring atoms (i.e., 3-12-membered heterocyclyl), 3 to 10 ring atoms (i.e., 3-10-membered heterocyclyl), 3 to 8 ring atoms (i.e., 3-8-membered heterocyclyl), 3 to 6 ring atoms (i.e., 3-6-membered heterocyclyl), 3 to 5 ring atoms (i.e., 3-5-membered heterocyclyl), 5 to 8 ring atoms (i.e., 5-8-membered heterocyclyl), or 5 to 6 ring atoms (i.e., 5-6-membered heterocyclyl).Examples of heterocyclyl groups are, for example, azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoquinol ... Includes isoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiroheterocyclyl rings include, but are not limited to, bicyclic and tricyclic ring systems such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl may be attached via either ring of the fused system.

[0044] As used herein, the term "oxo" refers to the moiety a=O.

[0045] The terms "optional" and "optionally," as used herein, mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur. Thus, the term "optionally substituted" infers that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms at the specified atom, moiety, or group may or may not be replaced by atoms, moieties, or groups other than hydrogen. By way of example, and not limitation, the phrase "methyl optionally substituted with one or more chloro" encompasses the moieties -CH, -CHCl, -CHCl, and -CCl.

[0046] Aspects and embodiments described herein as "comprising" are to be understood to include "consisting of" and "consisting essentially of" embodiments.

[0047] The term "pharmaceutically acceptable salt" of a given compound, as used herein, refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salt" includes, for example, salts with inorganic acids and salts with organic acids. Furthermore, if a compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from base compounds. See, for example, "Handbook of Pharmaceutical Salts Properties, Selection, and Use," International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), incorporated herein by reference. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Salts derived from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines.Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0048] Isotopically labeled forms of the compounds described herein can be prepared. Isotopically labeled compounds have the structures shown herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, for example, 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. In some embodiments, compounds of Formula (A) are provided in which one or more hydrogens are replaced with deuterium or tritium.

[0049] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with each other. By way of example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and the nature of the equilibrium between the tautomers, the compounds of this disclosure will be understood by those skilled in the art to include both the amide and imidic acid tautomers. Thus, for example, an amide-containing compound is understood to include its imidic acid tautomer. Similarly, an imidic acid-containing compound is understood to include its amide tautomer.

[0050] Prodrugs of the compounds disclosed herein or pharmaceutically acceptable salts thereof are also provided herein. Prodrugs are compounds that can be administered to an individual and release the compounds disclosed herein as parent drug compounds in vivo. It should be understood that prodrugs can be prepared by modifying functional groups in the parent drug compound so that the modifications are cleaved in vitro or in vivo to release the parent drug compound. See, for example, Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7, 255-270 (2008), which is incorporated herein by reference.

[0051] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may contain asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined in terms of absolute stereochemistry as (R)- or (S)- (or, in the case of amino acids, (D)- or (L)-). The present disclosure is intended to include all such possible isomers, as well as their racemic and optically pure forms, and mixtures thereof, in any proportion. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemates (or racemates of salts or derivatives) using, for example, chiral high-pressure liquid chromatography (HPLC) and chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the present disclosure is intended to include both E and Z geometric isomers. Similarly, cis and trans are used in their conventional sense to describe relative spatial relationships.

[0052] "Stereoisomers" refer to compounds consisting of the same atoms connected by the same bonds but having different three-dimensional structures that are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose structures are non-superimposable mirror images of each other. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other.

[0053] Where enantiomeric and / or diastereomeric forms of a given structure exist, a planar bond indicates that all stereoisomeric forms of the structure shown may exist, for example: [ka]

[0054] Where enantiomeric and / or diastereomeric forms of a given structure exist, the presence of a planar bond and "*" symbol indicates that the composition consists of at least 90% by weight of a single isomer of unknown stereochemistry, for example, [ka]

[0055] Where enantiomeric and / or diastereomeric forms of a given structure exist, a wedge or hash bond indicates that the composition consists of at least 90% by weight of a single enantiomer or diastereomer of the known stereochemistry, for example, [ka]

[0056] Combinations of the above notations may be used where applicable. Exemplary species may contain stereocenters with known stereochemistry and stereocenters with unknown stereochemistry, such as: [ka]

[0057] Combinations of the above notations may be used where applicable. Exemplary species may contain stereocenters with known stereochemistry and stereocenters with unknown stereochemistry, such as: [ka]

[0058] compound In one embodiment, a compound of formula (I): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is 0 or 1, n is 0, 1, or 2, and m+n is an integer of 1 to 2; Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 But H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; Q 1 but, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; (ii) C6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl, and R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0059] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2. In some embodiments, m is 0 and n is 1 or 2. In some embodiments, m is 0 and n is 1. In some embodiments, m is 0 and n is 2. In some embodiments, m is 1 and n is 0 or 1. In some embodiments, m is 1 and n is 0. In some embodiments, m is 1 and n is 1. In some embodiments, m+n is 1. In some embodiments, m+n is 2.

[0060] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 are each independently H or halo. In some embodiments, X 1 and X 2 are each independently H or F. In some embodiments, X 1 and X 2 are each independently H. In some embodiments, X 1 and X 2 are each independently halo. 1 and X 2 are each independently F. In some embodiments, X 1 and X 2 One of them is H and X 1 and X 2 The other of X is halo. 1 and X 2 One of them is H and X 1 and X 2 The other of these is F.

[0061] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 3is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 In some embodiments, X is optionally substituted with alkyl. 3 is H, isopropyl, or cyclopropyl, and X 3 The cyclopropyl in X is optionally substituted with one or more methyl. In some embodiments, X 3 is H. In some embodiments, X 3 is isopropyl. In some embodiments, X 3 is cyclopropyl and X 3 The cyclopropyl in X is optionally substituted with one or more methyl. In some embodiments, X 3 is cyclopropyl.

[0062] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 , X 2 , and X 3 are each H.

[0063] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH.

[0064] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y 1 and Y 2 are CH, and X 1 , X 2 , and X 3 are each H.

[0065] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y 1 and Y 2 are CH, respectively.

[0066] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) [ka] teeth, [ka] In some embodiments, the compound of formula (I) [ka] teeth, [ka] is.

[0067] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH.

[0068] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) is selected from the group consisting of: [ka] teeth, [ka] In some embodiments, the compound of formula (I) [ka] teeth, [ka] In some embodiments, the compound of formula (I) [ka] teeth, [ka] is.

[0069] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 In some embodiments, Q is optionally substituted with alkyl. 1 is C 6~8 is cycloalkyl, and Q 1 C 6~8 Cycloalkyl is one or more C 1~3In some embodiments, Q is optionally substituted with alkyl. 1 is C 6~8 is cycloalkyl, and Q 1 C 6~8 The cycloalkyl is optionally substituted with one or more methyl. In some embodiments, Q 1 teeth, [ka] is.

[0070] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 3 is H and Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 3 H, and C 6~8 is cycloalkyl, and Q 1 C 6~8 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0071] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 is C 6~20 aryl, and Q 1 C 6~20 Aryl is one or more R b and each R b are independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b The 5- to 20-membered heteroaryl may have one or more C 1~6In some embodiments, Q is optionally substituted with alkyl. 1 is C 6~10 aryl, and Q 1 C 6~10 Aryl is one or more R b and each R b are independently C 1~4 Alkyl, -C 1~4 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl may have one or more C 1~4 In some embodiments, Q is optionally substituted with alkyl. 1 is C 6~10 aryl, and Q 1 C 6~10 Aryl is one or more R b is optionally substituted with

[0072] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, each R b are independently C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b The 5- to 20-membered heteroaryl may have one or more C 1~6 In some embodiments, each R b are independently C 1~4 Alkyl, -C 1~4 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl may have one or more C 1~4 In some embodiments, each R bare independently methyl, isopropyl, sec-butyl, tert-butyl, methoxy, isopropoxy, sec-butoxy, tert-butoxy, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl may have one or more C 1~4 Optionally substituted with alkyl.

[0073] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b The 5- to 20-membered heteroaryl may have one or more C 1~6 In some embodiments, Q is optionally substituted with alkyl. 1 is phenyl and Q 1 The phenyl in b and each R b are independently C 1~4 Alkyl, -C 1~4 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl may have one or more C 1~4 Optionally substituted with alkyl.

[0074] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 teeth, [ka] In some embodiments, Q is selected from the group consisting of 1 teeth, [ka] In some embodiments, Q is selected from the group consisting of 1 teeth, [ka] In some embodiments, Q is selected from the group consisting of 1 teeth, [ka] In some embodiments, Q 1 teeth, [ka] is.

[0075] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 is a 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl may have one or more oxo or C 1~6 In some embodiments, Q is optionally substituted with alkyl. 1 is a 6- to 10-membered heterocyclyl, and Q 1 The 6- to 10-membered heterocyclyl may have one or more oxo or C 1~3 In some embodiments, Q is optionally substituted with alkyl. 1 teeth, [ka] is selected from the group consisting of:

[0076] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 is a 5- to 20-membered heteroaryl; Q1 is optionally substituted with one or more -NH2, and when m is 1, Q 1 In some embodiments, the 5-20 membered heteroaryl of Q contains at least one ring N. 1 is a 5- to 10-membered heteroaryl, and Q 1 is optionally substituted with one or more -NH2, and when m is 1, Q 1 The 5-10 membered heteroaryl of Q contains at least one ring N. In some embodiments, Q 1 is pyridinyl and Q 1 The pyridinyl in Q is optionally substituted with one or more -NH. 1 is pyridinyl. In some embodiments, Q 1 is thiophenyl. In some embodiments, Q 1 is pyrazolyl.

[0077] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q 1 teeth, [ka] In some embodiments, Q is selected from the group consisting of 1 teeth, [ka] is selected from the group consisting of:

[0078] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, R a is H, halo, -OH, or -NH-C(O)-C 1~3 In some embodiments, Ra is H. In some embodiments, R a is halo. In some embodiments, R a is F. In some embodiments, R a is —OH. In some embodiments, R a is -NH-C(O)-C 1~3 In some embodiments, R a is —OH. In some embodiments, R a is -NH-C(O)-tert-butoxy.

[0079] In some embodiments of a compound of formula (I), or any embodiment or variation thereof, e.g., a compound of formula (IA), (I-A1), (I-A2), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (I-B5), (IC), (ID), (IE), (I-E1), (I-E2), (IF), (I-F1), (IG), (I-G1), (I-G2), (I-G3), (I-G4), (IH), (I-H1), (I-H2), (I-H3), (I-H4), or (I-H5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] wherein m, n, X 1 , X 2 , X 3 , Y 1 , Y 2 , and R a is as defined elsewhere herein.

[0080] In some embodiments of a compound of formula (I), or any embodiment or variation thereof, e.g., a compound of formula (IA), (I-A1), (I-A2), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (I-B5), (IC), (ID), (IE), (I-E1), (I-E2), (IF), (I-F1), (IG), (I-G1), (I-G2), (I-G3), (I-G4), (IH), (I-H1), (I-H2), (I-H3), (I-H4), or (I-H5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, [ka] wherein m, n, X 1 , X 2 , X 3 , Y 1 , and Y 2 is as defined elsewhere herein.

[0081] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is phenyl and Q 1 The phenyl in band each R b are independently C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b The 5- to 20-membered heteroaryl may have one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 6-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl may have one or more C 1~3 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0082] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently C 1~3 Alkyl, -C 1~3 alkoxy, or —NH—C(O)—(3- to 6-membered heterocyclyl), and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is methyl or cyclopropyl, and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently methyl, methoxy, or —NH—C(O)-azetidinyl; R a is H.

[0083] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is the halo, and X 3 is C 1~3 is alkyl, and Q 1 is phenyl and Q 1 The phenyl in band each R b are independently C 1~3 alkyl, or -NH-C(O)-NH2, and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is F and X 3 is isopropyl and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently methyl or —NH—C(O)—NH; R a is H.

[0084] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 and X 2 are each independently H, and X 3 is C 1~3 is alkyl, and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently C 1~3 alkyl, and R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 and X 2 are each independently H, and X 3 is isopropyl and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently methyl, and Ra is H.

[0085] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is the halo, and X 3 is C 1~3 is alkyl, and Q 1 is phenyl and Q 1 The phenyl in b and each R b are independently 5-10 membered heteroaryl, and R b The 5- to 10-membered heteroaryl may have one or more C 1~3 optionally substituted with alkyl, R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is F and X 3 is isopropyl and Q 1 is phenyl and Q 1 The phenyl in b and each R b is independently oxazolyl or pyrazolyl, and R b The oxazolyl or pyrazolyl of R is optionally substituted with one or more methyl; a is H.

[0086] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0087] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 are CH, and X 1 and X 2are each independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 In some embodiments, m is 0, n is 1, and Y is alkoxy. 1 and Y 2 are CH, and X 1 and X 2 are each independently a halo; 3 is H, C 1~3 is alkyl, and Q 1 is phenyl and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently F, and X 3 is isopropyl and Q 1 is phenyl and R a is H.

[0088] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 are CH, and X 1 and X 2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 are CH, and X 1 and X 2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0089] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is the halo, and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and Q 1 is phenyl and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is the halo, and X 3 is isopropyl, cyclopropyl, or cyclobutyl, and Q 1 is phenyl and Ra is H.

[0090] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0091] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is phenyl and R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0092] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is the halo, and X 3 is C 3~6 is cycloalkyl, and Q 1 is phenyl and R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is the halo, and X 3 is cyclopropyl and Q 1 is phenyl and R a is H.

[0093] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 and X 2 are H and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and Q 1 is phenyl and R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 and X 2 are H and X 3 is isopropyl, cyclopropyl, or cyclobutyl, and Q 1 is phenyl and R a is H.

[0094] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1; n is 0, 1, or 2; m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 (i) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (ii) 5- to 20-membered heteroaryl, wherein Q is optionally substituted with alkyl; 1 is optionally substituted with one or more -NH2, and R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 (i) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (ii) 5- to 10-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, and R a is H, halo, -OH, or -NH-C(O)-C 1~3 It is an alkoxy.

[0095] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is C 1~6 is alkyl, and Q 1 is a 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl may have one or more oxo or C 1~6 optionally substituted with alkyl, R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is C 1~3 is alkyl, and Q 1 is a 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl may have one or more oxo or C 1~3 optionally substituted with alkyl, R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1and X 2 are each independently H, and X 3 is C 1~3 is alkyl, and Q 1 is indolinyl, dihydro-2H-benzo[d]imidazolyl, benzo[d]oxazolyl, or 3,4-dihydroquinolinyl, and Q 1 indolinyl, dihydro-2H-benzo[d]imidazolyl, benzo[d]oxazolyl, or 3,4-dihydroquinolinyl is optionally substituted with one or more oxo; a is H.

[0096] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is the halo, and X 3 is C 1~6 is alkyl, and Q 1 is a 3- to 15-membered heterocyclyl, and Q 1 is optionally substituted with one or more oxo; and R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is the halo, and X 3 is C 1~3 is alkyl, and Q 1 is a 3- to 10-membered heterocyclyl, and Q 1 is optionally substituted with one or more oxo; and R a is H. In some embodiments, m is 0, n is 1, and Y 1 is CH and Y 2 is N and X 1 is H and X 2 is F and X 3 is C 1~3 is alkyl, and Q 1is dihydro-2H-benzo[d]imidazolyl, benzo[d]oxazolyl, and Q is 1 is optionally substituted with one or more oxo or methyl, and R a is H.

[0097] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is the halo, and X 3 is C 1~6 is alkyl, and Q 1 is a 5- to 20-membered heteroaryl, and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is the halo, and X 3 is C 1~3 is alkyl, and Q 1 is a 5- to 20-membered heteroaryl, and R a is H. In some embodiments, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 is H and X 2 is F and X 3 is C 1~3 is alkyl, and Q 1 is 1H-benzo[d]imidazole, and R a is H.

[0098] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1 or 2, and Y 1 and Y 2 are each CH or Y 1 and Y 2One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C1~6 In some embodiments, m is 0, n is 1, and Y is alkoxy. 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0099] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 2, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6(iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0100] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 2, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H, and X 3 is C 1~6 is alkyl, and Q 1 is a 5- to 20-membered heteroaryl, and R a is H. In some embodiments, m is 0, n is 2, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H, and X 3 is C 1~3is alkyl, and Q 1 is a 5- to 10-membered heteroaryl, and R a is H. In some embodiments, m is 0, n is 2, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H, and X 3 is isopropyl and Q 1 is thiophenyl and R a is H.

[0101] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is 0 or 1, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R bBut independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0102] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is 0, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0103] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is 0, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is C 1~6 is alkyl, and Q1 is C 6~20 aryl, and R a is H. In some embodiments, m is 1, n is 0, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is C 1~3 is alkyl, and Q 1 is C 6~10 aryl, and R a is H. In some embodiments, m is 1, n is 0, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H, and X 3 is isopropyl and Q 1 is phenyl and R a is H.

[0104] In some embodiments of the compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1, n is 1, and Y 1 and Y 2 are each CH or Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl;6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0105] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 or (iv) 5- to 20-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0, n is 1, and Y is alkoxy. 1 and Y 2 are CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C1~3 optionally substituted with alkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl is one or more C 1~6 (iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0106] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, m+n is an integer from 1 to 2, and Y 1 and Y 2 are CH, and X 1 and X2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl is one or more C 1~6 (iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6In some embodiments, m is 0, n is 1, and m+n is an integer from 1 to 2, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H or halo, and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl is one or more C 1~6 (iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0107] In some embodiments of the compounds of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, and Y 1 and Y 2 are CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 is (i)C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 (ii) optionally substituted with alkyl; 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 (iii) 3- to 15-membered heterocyclyl, and Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 (iv) a 3- to 15-membered heterocyclyl optionally substituted with alkyl, or (iv) a 5- to 20-membered heteroaryl, wherein Q 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0, n is 1, and Y is alkoxy. 1 and Y 2 are CH, and X 1 and X 2 are each independently H or halo, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl is one or more C 1~6 (iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0108] In some embodiments of a compound of Formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0, n is 1, m+n is an integer from 1 to 2, and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 One of them is H and X 1 and X 2 the other of which is independently H or halo, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 optionally substituted with alkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R b The 5- to 10-membered heteroaryl is one or more C 1~6(iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more —NH2, with the proviso that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 In some embodiments, m is 0, n is 1, and m+n is an integer from 1 to 2, and Y 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are each independently H or halo, and X 3 is C 1~3 Alkyl, or C 3~6 is cycloalkyl, and Q 1 is (i)C 6~8 cycloalkyl, where Q 1 C 6~8 Cycloalkyl may contain one or more C 1~3 (ii) optionally substituted with alkyl; 6~10 aryl, and Q 1 C 6~10 The aryl may be one or more R b and each R b But independently, C 1~3 Alkyl, -C 1~3 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl; R bThe 5- to 10-membered heteroaryl is one or more C 1~6 (iii) 3- to 10-membered heterocyclyl, and Q 1 The 3- to 10-membered heterocyclyl is one or more oxo or C 1~3 or (iv) 5- to 10-membered heteroaryl, wherein Q is 1 is optionally substituted with one or more -NH2, provided that X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, R a is H, halo, -OH, or -NH-C(O)-C 1~6 It is an alkoxy.

[0109] As used herein, in some embodiments, the compound has the formula (IA): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, of formula (I), wherein: iX 4~8 However, independently, H, C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 optionally substituted with alkyl; ii.X 6 But X 4 or X 8 and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl; X 5 , X 7 , and X 4 or X 8 and the other of each independently is H, oxo, or C 1~6 is alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one cyclic N, and X 5 , X 7 , and X 4 or X 8 the other of which is, each independently, H or a further —NH2; or iii.X 7 But X 5 or X 8 and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl; X 4 , X 6 , and X 5 or X 8 and the other of each independently is H, oxo, or C 1~6 is alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one cyclic N, and X 4 , X 6 , and X 5 or X 8 and the other of each independently is H or —NH 2 .

[0110] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 4~8 are each independently H, C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 4~8 are each independently H, C 1~3 Alkyl, -C 1~3 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is independently one or more C 1~3 Optionally substituted with alkyl.

[0111] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 4~8 are each independently H.

[0112] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 4~8 One of them is C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 optionally substituted with alkyl; X 4~8 and the others are each independently H. In some embodiments, X 4~8 One of them is C 1~3 Alkyl, -C 1~3alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is independently one or more C 1~3 optionally substituted with alkyl; X 4~8 and the others are each independently H. In some embodiments, X 4~8 One of them is methyl, -OCH3, [ka] and X is selected from the group consisting of 4~8 The others of are each independently H.

[0113] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 6 is X 4 or X 8 and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl; X 5 , X 7 , and X 4 or X 8 and the other of each independently is H, oxo, or C 1~6 is alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one cyclic N, and X 5 , X 7 , and X 4 or X 8 and the other of each independently is H, or an additional -NH2.

[0114] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 6 is X 4 or X 8 and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl; X 4 , X 6 , and X 5 or X 8 and the other of each independently is H, oxo, or C 1~6 is alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one cyclic N, and X 4 , X 6 , and X 5 or X 8 and the other of each independently is H or —NH 2 .

[0115] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 4~8 One of them is C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 optionally substituted with alkyl; X 4~8 and the others are each independently H. In some embodiments, X 4~8 One of them is C 1~3 Alkyl, -C 1~3alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is independently one or more C 1~3 optionally substituted with alkyl; X 4~8 and the others are each independently H. In some embodiments, X 4~8 One of them is methyl, -OCH3, [ka] and X is selected from the group consisting of 4~8 The others of are each independently H.

[0116] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 6 is X 4 or X 8 and the atom to which they are attached together form ring A, and ring A is a 3- to 9-membered heterocyclyl, and the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 In some embodiments, ring A is a 5- to 6-membered heterocyclyl, and the 5- to 6-membered heterocyclyl of ring A is optionally substituted with alkyl. 1~3 In some embodiments, ring A is optionally substituted with alkyl. [ka] where # represents the point of attachment to the remainder of the molecule.

[0117] In some embodiments of the compound of formula (IA), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 6 is X 4 or X 8and together with the atoms to which they are attached form ring A, wherein ring A is a 5-8 membered heteroaryl, and the 5-8 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-8 membered heteroaryl of ring A contains at least one cyclic N. In some embodiments, ring A is a 5-8 membered heteroaryl, and the 5-8 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-8 membered heteroaryl of ring A contains at least one cyclic N. In some embodiments, ring A is [ka] where # represents the point of attachment to the rest of the molecule.

[0118] As used herein, in some embodiments, the compound has the formula (I-A1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein X 4 But H, C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 4 is H, C 1~3 Alkyl, -C 1~3 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is independently one or more C 1~3 Optionally substituted with alkyl.

[0119] As used herein, in some embodiments, the compound has the formula (I-A2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein X 6 But H, C 1~6 Alkyl, -C 1~6 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl is independently one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 6 is H, C 1~3 Alkyl, -C 1~3 alkoxy, -NH-C(O)-NH, -NH-C(O)-(3- to 10-membered heterocyclyl), or 5- to 10-membered heteroaryl, wherein the 5- to 10-membered heteroaryl is independently one or more C 1~3 Optionally substituted with alkyl.

[0120] As used herein, in some embodiments, the compound has the formula (IB): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein

[0121] In some embodiments of the compound of formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 are independently H or halo, and X 3 is H, C 1~6 Alkyl or C3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 1 and X 2 are independently H or F, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 In some embodiments, X is optionally substituted with alkyl. 1 and X 2 One of them is H and X 1 and X 2 The other is a halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 1 and X 2 One of them is H and X 1 and X 2 The other of these is F and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0122] In some embodiments of the compound of formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y 1 and Y 2 are CH, and X 1 and X 2 are independently H or halo, and X 3 is H, C 1~6 Alkyl or C3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 are CH, and X 1 and X 2 are independently H or F, and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 are CH, and X 1 and X 2 One of them is H and X 1 and X 2 The other is a halo, and X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 are CH, and X 1 and X 2 One of them is H and X 1 and X 2 The other of these is F and X 3 is H, C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0123] In some embodiments of the compound of formula (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are independently H or halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 are independently H or F, and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2 One of them is H and X 1 and X 2 The other is a halo, and X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, Y is optionally substituted with alkyl. 1 and Y 2 One of them is N and Y 1 and Y 2 The other of these is CH, and X 1 and X 2One of them is H and X 1 and X 2 The other of them is F and X 3 is H, C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0124] As used herein, in some embodiments, the compound is represented by formula (I-B1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, of any of the foregoing.

[0125] In some embodiments of the compound of Formula (I-B1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 1 and X 2 are independently halo and X 3 is C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 1 and X 2 are independently F and X 3 is C 1~3 Alkyl, or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0126] In some embodiments, the compound has formula (I-B2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0127] In some embodiments of the compound of Formula (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 2 is the halo, and X 3 is C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 2 is F and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0128] In some embodiments, the compound has formula (I-B3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0129] In some embodiments of the compound of Formula (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 3 is C 1~6 Alkyl or C3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0130] As used herein, in some embodiments, the compound is represented by formula (I-B4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, of any of the foregoing.

[0131] In some embodiments, the compound has formula (I-B5): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0132] In some embodiments of the compound of Formula (I-B5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 2 is the halo, and X 3 is C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6In some embodiments, X is optionally substituted with alkyl. 2 is F and X 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0133] In some embodiments, the compound has formula (I-B6): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0134] In some embodiments of the compound of Formula (I-B6), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X 3 is C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 In some embodiments, X is optionally substituted with alkyl. 3 is C 1~3 Alkyl or C 3~6 is cycloalkyl, and X 3 C 3~6 Cycloalkyl is one or more C 1~3 Optionally substituted with alkyl.

[0135] As used herein, in some embodiments, the compound has the formula (IC): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one ring N.

[0136] As used herein, in some embodiments, the compound has the formula (ID): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C 1~6 optionally substituted with alkyl, or 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-14 membered heteroaryl of ring A contains at least one ring N.

[0137] In some embodiments of the compound of Formula (IC), (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, ring A is a 5- to 6-membered heterocyclyl, and the 5- to 6-membered heterocyclyl of ring A is selected from the group consisting of one or more oxo or C 1~3 In some embodiments, ring A is optionally substituted with alkyl. [ka] where # represents the point of attachment to the remainder of the molecule.

[0138] In some embodiments of a compound of Formula (IC), or (ID), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, ring A is a 5-8 membered heteroaryl, and the 5-8 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-8 membered heteroaryl of ring A contains at least one cyclic N. In some embodiments, ring A is a 5-8 membered heteroaryl, and the 5-8 membered heteroaryl of ring A is optionally substituted with one or more -NH2, and when m is 1, the 5-8 membered heteroaryl of ring A contains at least one cyclic N. In some embodiments, ring A is [ka] where # represents the point of attachment to the rest of the molecule.

[0139] As used herein, in some embodiments, the compound has the formula (IE): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0140] As used herein, in some embodiments, the compound has the formula (I-E1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0141] As used herein, in some embodiments, the compound is represented by formula (I-E2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0142] As used herein, in some embodiments, the compound has the formula (IF): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0143] As used herein, in some embodiments, the compound has the formula (I-F1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0144] As used herein, in some embodiments, the compound has the formula (IG): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0145] In some embodiments, the compound has the formula (I-G1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0146] In some embodiments, the compound has the formula (I-G2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0147] In some embodiments, the compound has the formula (I-G3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0148] In some embodiments, the compound has the formula (I-G4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0149] In some embodiments, the compound has the formula (IH): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0150] In some embodiments, the compound has formula (I-H1): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0151] In some embodiments, the compound has formula (I-H2): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0152] In some embodiments, the compound has formula (I-H3): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0153] In some embodiments, the compound has formula (I-H4): [ka] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0154] In some embodiments of a compound of Formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1.

[0155] Compound names contained in Table 1 and for all intermediates and compounds were generated using ChemDraw® Professional software version 17.1.1.0 or Collaborative Drug Discovery Inc. (CDD) CDD Vault update#3.

[0156] A KNIME workflow was created to retrieve structures from the internal ChemAxon Compound Registry, generate canonical smiles using the RDKit Canon SMILES node, remove stereochemistry using the ChemAxon / Infocom MolConverter node, and name the structures using the ChemAxon / Infocom Naming node. The following shows the versions of the KNIME Analytics Platform and extensions used in the workflow: ·Knime Analytics Platform 4.2.2 RDKit KNIME Integration 4.0.1.v202006261025 (This extension includes the RDKit Canon SMILES node) ChemAxon / Infocom Marvin Extensions Feature 4.3.0v202100 (This extension includes the MolConverter node) ChemAxon / Infocom JChem Extensions Feature 4.3.0v202100 (This extension includes the Naming node) [Table 1] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10]

[0157] Provided herein, in some embodiments, is a compound of Formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from the group consisting of: 2-({[4-(propan-2-yl)phenyl](thiophen-2-yl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[4-(propan-2-yl)phenyl](thiophen-2-yl)methyl}carbamoyl)cyclohexane-1-carboxylic acid; 2-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(2-methylphenyl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(2-methoxyphenyl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(4-cyclopropylphenyl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[3-fluoro-4-(propan-2-yl)phenyl](phenyl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({phenyl[5-(propan-2-yl)pyridin-2-yl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-[({6,6-dimethylspiro[3.3]heptan-2-yl}(phenyl)methyl)carbamoyl]cyclopentane-1-carboxylic acid; 3-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(4-cyclobutylphenyl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[4-(propan-2-yl)phenyl](1H-pyrazol-5-yl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(2-oxo-2,3-dihydro-1H-indol-7-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(2-aminopyridin-3-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(4-cyclobutylphenyl)(2-methylphenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[3-fluoro-4-(propan-2-yl)phenyl](1H-pyrazol-5-yl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(4-cyclopropylphenyl)(2-methylphenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 4-Fluoro-2-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[2-(carbamoylamino)phenyl][3-fluoro-4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[3-fluoro-4-(propan-2-yl)phenyl](2-methylphenyl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(2-methylphenyl)[5-(propan-2-yl)pyridin-2-yl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 4-Hydroxy-2-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(4-cyclobutyl-3-fluorophenyl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(4-cyclopropyl-3-fluorophenyl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 4-Hydroxy-2-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(5-cyclobutylpyridin-2-yl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[4-(1-methylcyclopropyl)phenyl](phenyl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[2-(azetidin-3-amido)phenyl][4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(5-cyclopropylpyridin-2-yl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 4-{[(TERT-butoxy)carbonyl]amino}-2-({phenyl[4-(propan-2-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-{[(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)[4-(propan-2-yl)phenyl]methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[3,5-difluoro-4-(propan-2-yl)phenyl](phenyl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[3-fluoro-4-(propan-2-yl)phenyl](1-methyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-4-yl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-{[(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methyl]carbamoyl}cyclopentane-1-carboxylic acid; 2-({[6-fluoro-5-(propan-2-yl)pyridin-2-yl](1H-indazol-6-yl)methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[6-fluoro-5-(propan-2-yl)pyridin-2-yl][3-(1H-pyrazol-5-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[6-fluoro-5-(propan-2-yl)pyridin-2-yl][3-(1,2-oxazol-5-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; 2-({[6-fluoro-5-(propan-2-yl)pyridin-2-yl][3-(1,3-oxazol-5-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; and 2-({[6-fluoro-5-(propan-2-yl)pyridin-2-yl][3-(1-methyl-1H-pyrazol-5-yl)phenyl]methyl}carbamoyl)cyclopentane-1-carboxylic acid; or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0158] Provided herein, in some embodiments, is a compound of Formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from the group consisting of: (1S,2R)-2-(((S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(1-methyl-1H-pyrazol-5-yl)phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(oxazol-5-yl)phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(isoxazol-5-yl)phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(3-(1H-pyrazol-5-yl)phenyl)(6-fluoro-5-isopropylpyridin-2-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(6-fluoro-5-isopropylpyridin-2-yl)(1H-indazol-6-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(3,5-difluoro-4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxo-2,3-dihydrobenzo[d]oxazol-7-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxo-2,3-dihydrobenzo[d]oxazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R,2R or 2S,4R or 4S)-4-((tert-butoxycarbonyl)amino)-2-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(5-cyclopropylpyridin-2-yl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(2-(azetidine-3-carboxamido)phenyl)(4-isopropylphenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-(1-methylcyclopropyl)phenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(5-cyclobutylpyridin-2-yl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R,2R or 2S,4R or 4S)-4-hydroxy-2-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-cyclopropyl-3-fluorophenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-cyclobutyl-3-fluorophenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R, 2R or 2S, 4S or 4R)-4-hydroxy-2-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(5-isopropylpyridin-2-yl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(2-ureidophenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R,2R or 2S,4R or 4S)-4-fluoro-2-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-cyclopropylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1H-pyrazol-5-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-cyclobutylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(2-aminopyridin-3-yl)(4-isopropylphenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxoindolin-7-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(1H-pyrazol-5-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R,3R or 3S)-3-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-cyclobutylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S or 1R,2R or 2S)-2-(((R)-(6,6-dimethylspiro[3.3]heptan-2-yl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(5-isopropylpyridin-2-yl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(3-fluoro-4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-cyclopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(2-methoxyphenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((S)-(4-isopropylphenyl)(phenyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(thiophen-2-yl)methyl)carbamoyl)cyclohexane-1-carboxylic acid; (1R or 1S,2S or 2R)-2-(((S or R)-(4-isopropylphenyl)(thiophen-2-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1R or 1S,2S or 2R)-2-(((R or S)-(4-isopropylphenyl)(thiophen-2-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-(((R)-(4-isopropylphenyl)(thiophen-2-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; and (1S or 1R, 2R or 2S)-2-(((S or R)-(4-isopropylphenyl)(thiophen-2-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid; or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0159] Treatment method Provided herein are methods for modulating GYS1 in a cell, the methods comprising exposing the cell to (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, is selective for GYS1 over GYS2. In some embodiments, the compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, is 500-fold, 1,000-fold, 1,500-fold, or 1,700-fold selective for GYS1 over GYS2.

[0160] Provided herein are methods for inhibiting GYS1 in a cell, the method comprising exposing the cell to (i) a composition comprising an effective amount of a GYS1 inhibitor, or (ii) a pharmaceutical composition comprising an effective amount of a GYS1 inhibitor and one or more pharmaceutically acceptable excipients. In some embodiments, the GYS1 inhibitor is a small molecule. In some embodiments, the GYS1 inhibitor is selective for GYS1 over GYS2. In some embodiments, the GYS1 inhibitor is 500-fold, 1,000-fold, 1,500-fold, or 1,700-fold selective for GYS1 over GYS2.

[0161] Provided herein are methods for inhibiting GYS1 in a cell, the method comprising exposing the cell to (i) a composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0162] In some embodiments, the compound of Formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selective for GYS1 over GYS2. In some embodiments, the compound of Formula (I), or any variation or embodiment thereof, or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is 500-fold, 1,000-fold, 1,500-fold, or 1,700-fold selective for GYS1 over GYS2. In some embodiments, the individual has a GYS1-mediated disease, disorder, or condition selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease. In some embodiments, the GYS1-mediated disease, disorder, or condition is cancer. In some embodiments, the GYS1-mediated disease, disorder, or condition is selected from the group consisting of Ewing's sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma (GRCC) breast cancer, non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML). In some embodiments, the GYS1-mediated disease, disorder, or condition is Pompe disease. In some embodiments, the GYS1-mediated disease, disorder, or condition is late-onset Pompe disease (LOPD).

[0163] Provided herein are methods of reducing tissue glycogen stores in an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0164] Provided herein is a method of inhibiting glycogen synthesis in an individual in need thereof, comprising administering to the individual an effective amount of (i) a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0165] Provided herein are methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the GYS1-mediated disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease. In some embodiments, the GYS1-mediated disease, disorder, or condition is cancer. In some embodiments, the GYS1-mediated disease, disorder, or condition is selected from the group consisting of Ewing's sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma (GRCC) breast cancer, non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML).

[0166] Provided herein are methods of treating a glycogen storage disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, glycogen levels in the individual are reduced during treatment. In some embodiments, glycogen levels in muscle are reduced. In some embodiments, glycogen levels in skeletal muscle are reduced. In some embodiments, glycogen levels are reduced by at least 10%, at least 20%, at least 30%, or at least 50% upon administration of the compound. In some embodiments, the compounds provided herein are effective in treating a lysosomal disorder. In some embodiments, the glycogen storage disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease.

[0167] Provided herein are methods of treating a glycogen storage disease, disorder, or condition in an individual in need thereof, comprising administering to the individual (i) a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, glycogen levels in the individual are reduced during treatment. In some embodiments, glycogen levels in muscle are reduced. In some embodiments, glycogen levels in skeletal muscle are reduced. In some embodiments, glycogen levels are reduced by at least 10%, at least 20%, at least 30%, or at least 50% upon administration of the compound. In some embodiments, the compounds provided herein are effective in treating a lysosomal disorder. In some embodiments, the glycogen storage disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease.

[0168] Provided herein are methods of treating Pompe disease in an individual in need thereof, comprising administering to the individual (i) a composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising an effective amount of a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the individual has infantile-onset Pompe disease. In some embodiments, the individual has non-classical infantile-onset Pompe disease. In some embodiments, the individual has late-onset Pompe disease. In some embodiments, the individual is deficient in acid alpha-glucosidase (GAA). In some embodiments, the individual has reduced expression of GAA.

[0169] Provided herein are methods of treating Pompe disease in an individual in need thereof, comprising administering to the individual (i) a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. In some embodiments, the individual has infantile-onset Pompe disease. In some embodiments, the individual has non-classical infantile-onset Pompe disease. In some embodiments, the individual has late-onset Pompe disease. In some embodiments, the individual is deficient in acid alpha-glucosidase (GAA). In some embodiments, the individual has reduced expression of GAA.

[0170] In some embodiments, the compounds provided herein reduce and / or eliminate one or more symptoms associated with Pompe disease. In some embodiments, the compounds reduce and / or eliminate muscle weakness, poor muscle tone, enlarged liver, abnormal growth and weight gain, difficulty breathing, eating disorders, respiratory infections, hearing problems, delayed motor skills, enlarged heart, fatigue, lung infections, frequent falls, or irregular heartbeat. In some embodiments, the compounds provided herein slow the progression of Pompe disease.

[0171] In some embodiments, the compounds provided herein extend the lifespan of an individual, hi some embodiments, the lifespan is extended by at least 5 years, at least 10 years, or at least 20 years after treatment.

[0172] In some embodiments, compounds provided herein prevent, reduce, or delay muscle weakness. In some embodiments, muscle weakness is determined by manual muscle testing, sit-to-stand test, heel-raise test, hand-held dynamometry, or hand grip dynamometry. In some embodiments, strength is graded according to the following scale: 0: no visible muscle contraction; 1: muscle contraction, but no or slight movement; 2: limb movement, but not against gravity; 3: movement against gravity, but not against resistance; 4: movement against at least some resistance is produced by the tester; 5: full strength.

[0173] Also provided herein are methods for inhibiting the GYS1 enzyme in an individual, comprising administering to the individual an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the GYS1 enzyme is human GYS1 (hGYS1). In some embodiments, the compounds provided herein inhibit GYS1 at concentrations less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein inhibit GYS1 at concentrations between 1 and 10 μM, between 0.01 and 1 μM, or between 0.01 and 10 μM.

[0174] In some embodiments, the compound has an IC of less than 10 nM, less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. 50 In some embodiments, the compounds provided herein have an IC of 1-10 nM, 1-10 μM, 0.01-1 μM, 0.01-10 μM, or 0.001-0.01 μM. 50 It has.

[0175] In some embodiments, glycogen synthesis is inhibited upon administration of a compound provided herein, ie, glycogen synthesis is reduced by at least 10%, at least 20%, at least 40%, or at least 50% upon administration.

[0176] In some embodiments, the individual being treated is a juvenile or infant, hi some embodiments, the individual is under 10 years old, under 9 years old, under 8 years old, under 7 years old, under 6 years old, under 5 years old, under 4 years old, under 3 years old, under 2 years old, or under 1 year old.

[0177] In some embodiments, these methods further comprise enzyme replacement therapy (ERT). Exemplary ERTs include alglucosidase alfa (human recombinant alpha-glucosidase (human GAA)) and those described in Byrne BJ et al (2011). Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 103:1-11, incorporated herein by reference in its entirety. In some embodiments, the ERT is selected from the group consisting of Myozyme and Lumizyme. In some embodiments, the ERT is Myozyme. In some embodiments, the ERT is Lumizyme. In some embodiments, the individual has an advanced glycogen storage disease. In some embodiments, the individual has late-onset Pompe disease. Accordingly, provided herein are methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising: (a) subjecting the individual to glycogen substrate reduction therapy, such as administering to the individual an effective amount of (i) a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (ii) a pharmaceutical composition comprising a compound of Formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (b) enzyme replacement therapy. In some embodiments, the GYS1-mediated disease, disorder, or condition is Pompe disease, such as late-onset Pompe disease. In some embodiments, the compound of Formula (I) is selective for GYS1 over GYS2. In some embodiments, compounds of formula (I) are 500-fold or 1,000-fold or 1,500-fold or 1,700-fold selective for GYS1 over GYS2.

[0178] In some embodiments, the individual has a mutation in the GAA gene. In some embodiments, the mutation reduces the level of GAA protein. In some embodiments, the mutation is a loss-of-function mutation. In some embodiments, the mutation is a missense mutation. In some embodiments, the mutation is a deletion. In some embodiments, the mutation is a recessive mutation. In some embodiments, the mutation is a splicing variant.

[0179] In some of the foregoing embodiments, the administration is oral.

[0180] kit The present disclosure further provides kits for carrying out the methods of the present invention. The kits may include a compound as described herein or a pharmaceutically acceptable salt thereof and suitable packaging. The kits may include one or more containers containing any of the compounds described herein. In one embodiment, the kits include a compound of the present disclosure or a pharmaceutically acceptable salt thereof and a label and / or instructions for using the compound in the treatment of a disease or disorder described herein. The kits may include a unit dosage form of the compound.

[0181] Provided herein is a kit comprising (i) a composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof. Also provided herein is a kit comprising (i) a pharmaceutical composition comprising an effective amount of a compound of formula (I), or any variant or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients, and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

[0182] Provided herein is a kit comprising (i) a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof. Also provided herein is a kit comprising (i) a pharmaceutical composition comprising an effective amount of a compound of formula (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients, and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

[0183] Also provided is an article of manufacture comprising, in a suitable container, a compound of formula (I), or any variation or embodiment thereof as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is an article of manufacture comprising, in a suitable container, a pharmaceutical composition comprising, in a suitable container, a compound of formula (I), or any variation or embodiment thereof as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. The container may be a vial, bottle, ampoule, pre-filled syringe, or intravenous bag.

[0184] Preparation method The present disclosure further provides methods for preparing the compounds of the present invention. Provided herein, in some aspects, are methods for preparing a compound of Formula (I), (IA), (I-A1), (I-A2), (IB), (I-B1), (I-B2), (I-B3), (I-B4), (I-B5), (IC), (ID), (IE), (I-E1), (I-E2), (IF), (I-F1), (IG), (I-G1), (I-G2), (I-G3), (I-G4), (IH), (I-H1), (I-H2), (I-H3), (I-H4), or (I-H5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0185] In some embodiments, the process for preparing a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises: (a) Formula (I-1): [ka] or a salt thereof (wherein Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 teeth, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C1~6 optionally substituted with alkyl; (ii) C 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl in the presence of a coupling reagent to form a compound of formula (I-2): [ka] (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer of 1 to 2, R a is H, halo, -OH, or -NH-C(O)-C 1~6 is an alkoxy, and PG is a protecting group. to react with a compound of formula (I-3): [ka] (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer of 1 to 2; Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl; Q 1 teeth, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; (ii) C 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl; R a is H, halo, -OH, or -NH-C(O)-C 1~6 is alkoxy, and PG is a protecting group) followed by providing a compound of (b) contacting the compound of formula (I-3) with a deprotecting agent to provide a compound of formula (I).

[0186] In some embodiments, the protecting group is an alkyl protecting group. In some embodiments, the protecting group is a tert-butoxy group. In some embodiments, the protecting group is an allyl protecting group. In some embodiments, the protecting group is a propenyl group.

[0187] In some embodiments, the coupling reagent comprises EDCCl, TCFH, or T3P. In some embodiments, the method further comprises the presence of a base. In some embodiments, the base comprises an amine. In some embodiments, the amine is DMAP, NMM, or a trialkylamine. In some embodiments, the coupling reagent is N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate (TFCH).

[0188] In some embodiments, the deprotecting agent comprises an acid. In some embodiments, the acid is HCl, TFA, or a barbituric acid. In some embodiments, the deprotecting agent comprises tetrakis(triphenylphosphine)palladium(0). In some embodiments, the deprotecting agent comprises tetrakis(triphenylphosphine)palladium(0) and a barbituric acid.

[0189] In some embodiments, the process for preparing a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises: Formula (I-1): [ka] or a salt thereof (wherein Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 is H, C 1~6 Alkyl or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl, and Q 1 teeth, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; (ii) C 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R band each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 is C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl in the presence of a coupling reagent to form a compound of formula (I-4): [ka] (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer of 1 to 2; Y 1 and Y 2 are each CH, or Y 1 and Y 2 One of them is N and Y 1 and Y 2 the other of which is CH, X 1 and X 2 are each independently H or halo; X 3 is H, C 1~6 Alkyl, or C 3~10 is cycloalkyl, and X 3 C 3~10 Cycloalkyl is one or more C 1~6 optionally substituted with alkyl; Q 1 teeth, (I C 6~10 cycloalkyl, where Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl; (ii) C 6~20 aryl, and Q 1 C 6~20 The aryl may be one or more R b and each R b But independently, C 1~6 Alkyl, -C 1~6 alkoxy, —NH—C(O)—NH, —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R b 5-20 membered heteroaryl is one or more C 1~6 optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, where Q 1 The 3- to 15-membered heterocyclyl is one or more oxo or C 1~6 optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, where Q 1 is optionally substituted with one or more —NH2, and m is 1, then Q 1 wherein the 5- to 20-membered heteroaryl contains at least one cyclic N; However, X 3 If is H, then Q 1 C 6~10 is cycloalkyl, and Q 1 C 6~10 Cycloalkyl may contain one or more C 1~6 optionally substituted with alkyl, and R a is H, halo, -OH, or -NH-C(O)-C 1~6 alkoxy) to provide a compound of formula (I).

[0190] In some embodiments, the coupling reagent comprises a base. In some embodiments, the base comprises an amine. In some embodiments, the base comprises a tertiary amine. In some embodiments, the amine is DIEA or a trialkylamine. [Example]

[0191] The following synthetic reaction schemes, detailed in the schemes and examples, are intended to illustrate only some of the ways in which the compounds of the present disclosure, or embodiments or aspects thereof, may be synthesized. As will be apparent to one of ordinary skill in the art, various modifications to these synthetic reaction schemes can be made.

[0192] The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if necessary using conventional techniques, including, but not limited to, filtration, distillation, crystallization, chromatography, etc. Such materials can be characterized using conventional means, including physical constants and spectral data.

[0193] While certain exemplary embodiments are shown and described herein, the compounds of the present disclosure, or any variation or embodiment thereof, may be prepared using appropriate starting materials according to the methods generally described herein and / or by methods available to those skilled in the art.

[0194] Synthesis Example As shown in the following schemes and examples, in certain exemplary embodiments, compounds of formula (I), or any variation or embodiment thereof as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are prepared according to general procedures. The following general methods, and others known to synthetic chemists of ordinary skill in the art, may be applied to all formulas, variations, embodiments, and species described herein.

[0195] Scheme Scheme 1 [ka] Compounds of formula S1-4 can be prepared as outlined in general Scheme 1. Amide coupling of monoprotected carboxylic acid S1-1 with amine S1-2 using a coupling reagent such as N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate (TFCH) and a base such as N-methylimidazole (NMI) in an aprotic solvent such as acetonitrile provides amide S1-3. Removal of the allyl protecting group using a metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and barbituric acid in a solvent such as DCM provides compounds of formula S1-4. If desired, compounds of formula S1-4 can be further purified by chiral SFC.

[0196] Scheme 2 [ka] Compounds of formula S2-3, S2-4, S2-5, and S2-6 can be prepared as outlined in general Scheme 2. Reaction of anhydride S2-1 with amine S2-2 using a tertiary amine base such as DIEA in an aprotic solvent such as THF provides compounds of formula S2-3, S2-4, S2-5, and S2-6. These compounds may be further purified using methods such as chiral SFC to provide the compounds as single stereoisomers.

[0197] Abbreviations used are conventional in the art and are taken from the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed. The following examples are intended to be illustrative only and not limiting in any way. [Table 11]

[0198] Intermediate A-1: ​​Synthesis of (R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methanaminium chloride [ka] Step a: To a solution of 3-fluoro-4-isopropylbenzaldehyde (700 mg, 4.21 mmol, 1 equiv.) and 2-methylpropane-2-sulfinamide (816 mg, 6.74 mmol, 1.6 equiv.) in DCM (20 mL) was added CsCO (4.12 g, 12.6 mmol, 3 equiv.). The resulting mixture was then warmed to 40 °C and stirred for 2 h. The reaction mixture was then filtered, diluted with water, and the filtrate was extracted with DCM (3 × 20 mL). The combined organic extracts were washed with HO (30 mL) and brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (E)-N-(3-fluoro-4-isopropylbenzylidene)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 14 H 20 Calculated for FNOS: 270.1; measured value 270.2.

[0199] Step b: To a solution of 4-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (1.00 g, 4.40 mmol, 1 equiv.) in THF (20 mL) at −65° C., n-BuLi (2.50 M in hexanes, 7.05 mL, 4 equiv.) was added dropwise under a N atmosphere. The resulting mixture was stirred at −65° C. for 3 hours. Then, a solution of (E)-N-(3-fluoro-4-isopropylbenzylidene)-2-methylpropane-2-sulfinamide (2.37 g, 8.81 mmol, 2 equiv.) in THF (5 mL) was added dropwise to the reaction mixture at −65° C. The resulting mixture was then warmed to 25° C. and stirred for 2 hours. The reaction mixture was then cooled to 0° C. and quenched by the addition of saturated aqueous NH4Cl solution (20 mL). The resulting mixture was then warmed to room temperature and diluted with water (10 mL). The resulting biphasic mixture was extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give N-((3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-2-methylpropane-2-sulfinamide as a mixture of isomers. These isomers were separated by preparative HPLC (column: Phenomenex Luna C18) to give N-((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-2-methylpropane-2-sulfinamide as the first eluting isomer. LC-MS(ESI):m / z:[M+H] + C 22 H 28 Calculated for FN3O2S: 418.2; found 418.2.

[0200] Step c: To a mixture of N-((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)-2-methylpropane-2-sulfinamide (120 mg, 287 μmol, 1.00 equiv.) in EtOAc (1 mL) at 0° C., HCl / EtOAc (5 mL) was added. The resulting mixture was then stirred at 0° C. for 1 h. The reaction mixture was then filtered, and the filter cake was washed with MTBE (3×5 mL). The resulting solid was dried under reduced pressure to give (R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methanaminium chloride.

[0201] Intermediate A-2: Synthesis of (3-fluoro-4-isopropylphenyl)(o-tolyl)methanaminium chloride [ka] Step a: To a solution of (E)-N-(3-fluoro-4-isopropylbenzylidene)-2-methylpropane-2-sulfinamide (1.5 g, 5.57 mmol, 1 equiv.) in DCM (15 mL) at 0 °C, o-tolylmagnesium bromide (0.9 M in diethyl ether, 15.4 mL, 2.5 equiv.) was added dropwise under a N atmosphere. The resulting mixture was warmed to 20 °C and stirred for 2 h. The reaction solution was then quenched with HO (30 mL), and the resulting biphasic mixture was extracted with EtOAc (3 × 30 mL). The organic extracts were combined, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give N-((3-fluoro-4-isopropylphenyl)(o-tolyl)methyl)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 21 H 28 Calculated for FNOS: 362.2; Measured: 362.2.

[0202] Step b: To a solution of N-((3-fluoro-4-isopropylphenyl)(o-tolyl)methyl)-2-methylpropane-2-sulfinamide (2.6 g, 7.19 mmol, 1 equiv) in EtOAc (5 mL) at 0 °C was added HCl / EtOAc (10 mL). The resulting mixture was warmed to 20 °C and stirred for 1.5 h. The reaction was then concentrated under reduced pressure to give (3-fluoro-4-isopropylphenyl)(o-tolyl)methanaminium chloride. LC-MS (ESI): m / z [M-NH3] + C 17 H 20 Calculated for FN: 241.1; Measured: 241.2.

[0203] Intermediate A-3: Synthesis of (6-fluoro-5-isopropylpyridin-2-yl)(1H-indazol-6-yl)methanaminium chloride [ka] Step a: To a solution of 6-bromo-1H-indazole (8 g, 40.6 mmol, 1 equiv.) in DMF (50 mL) was added trityl chloride (TrtCl, 12.4 g, 44.6 mmol, 1.1 equiv.) and TEA (7.06 mL, 50.7 mmol, 1.25 equiv.). The resulting mixture was stirred at 25 °C for 16 h. The reaction mixture was then diluted with water, and the resulting biphasic mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic extracts were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was triturated with MTBE (30 mL) and filtered to give 6-bromo-1-trityl-1H-indazole, which was carried on to the next step without further purification or characterization.

[0204] Step b: To a mixture of 6-bromo-1-trityl-1H-indazole (16.7 g, 38.0 mmol, 1 equiv.), potassium vinyltrifluoroborate (10.1 g, 76.0 mmol, 2 equiv.), and TEA (15.8 mL, 14.0 mmol, 3 equiv.) in i-PrOH (160 mL) was added Pd(dppf)Cl·CHCl (1.55 g, 1.90 mmol, 0.05 equiv.) under N. The resulting mixture was then degassed and placed under a N atmosphere. The reaction mixture was then warmed to 100 °C and stirred under N for 2 h. After cooling, the mixture was filtered, and the filter cake was washed with ethyl acetate (3 × 100 mL). The combined filtrate was concentrated, and the resulting crude residue was purified by column chromatography to give 1-trityl-6-vinyl-1H-indazole. LC-MS(ESI):m / z:[2M+Na] + C 28 H 22 Calculated for N2: 795.4; measured 795.3.

[0205] Step c: To a solution of 1-trityl-6-vinyl-1H-indazole (14.2 g, 36.7 mmol, 1 equiv) in THF:HO (5:1) (300 mL) at 0 °C, NaIO (31.4 g, 146 mmol, 4 equiv) and KOsO·2HO (676 mg, 1.84 mmol, 0.05 equiv) were added. The resulting mixture was warmed to 50 °C and stirred for 1 h. The reaction mixture was then cooled to 25 °C and quenched with saturated aqueous NaSO (100 mL). The resulting mixture was extracted with ethyl acetate (3 × 100 mL), and the combined extracts were dried over NaSO, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to give 1-trityl-1H-indazole-6-carbaldehyde.

[0206] Step d: To a solution of 1-trityl-1H-indazole-6-carbaldehyde (7.3 g, 18.8 mmol, 1 equiv.) in DCM (75 mL) was added CsCO (6.74 g, 20.7 mmol, 1.1 equiv.) and 2-methylpropane-2-sulfinamide (2.51 g, 20.6 mmol, 1.1 equiv.). The mixture was then warmed to 40 °C and stirred for 16 h. The reaction mixture was then filtered, and the filter cake was washed with ethyl acetate (3 × 100 mL). The filtrate was then filtered and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (E)-2-methyl-N-((1-trityl-1H-indazol-6-yl)methylene)propane-2-sulfinamide.

[0207] Step e: To a solution of 6-bromo-2-fluoro-3-isopropylpyridine (665 mg, 3.05 mmol, 1.5 equiv) in THF (5 mL) at −78° C. was added n-BuLi (1.22 mL, 2.5 M, 1.5 equiv) dropwise under N. The resulting mixture was stirred at −78° C. for 0.5 h. After this time, (E)-2-methyl-N-((1-trityl-1H-indazol-6-yl)methylene)propane-2-sulfinamide (1 g, 2.03 mmol, 1 equiv) in THF (5 mL) cooled to −78° C. under N was added, and the resulting mixture was stirred at −78° C. for 4 h. The reaction was then quenched with saturated aqueous NH.sub.4Cl (20 mL), and the resulting biphasic mixture was extracted with ethyl acetate (3 × 20 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give N-((6-fluoro-5-isopropylpyridin-2-yl)(1-trityl-1H-indazol-6-yl)methyl)-2-methylpropane-2-sulfinamide.

[0208] Step f: To a solution of N-((6-fluoro-5-isopropylpyridin-2-yl)(1-trityl-1H-indazol-6-yl)methyl)-2-methylpropane-2-sulfinamide (600 mg, 951 μmol, 1 equiv.) in EtOAc (3 mL) at 0° C. was added HCl / EtOAc (4 M, 3 mL, 12.6 equiv.). The resulting mixture was then warmed to 40° C. and stirred for 16 h. The reaction mixture was then filtered to give (6-fluoro-5-isopropylpyridin-2-yl)(1H-indazol-6-yl)methanaminium chloride. LC-MS (ESI): m / z [M-NH3] + C 16 H 17 Calculated for FN4: 268.1; Measured: 268.2.

[0209] Intermediate A-4: Synthesis of (3-(1H-pyrazol-5-yl)phenyl)(6-fluoro-5-isopropylpyridin-2-yl)methanaminium chloride [ka] Step a: To a solution of 5-(3-bromophenyl)-1H-pyrazole (408 mg, 1.83 mmol, 1.5 equiv) in THF (3 mL) at −60° C. under N2, n-BuLi (2.5 M, 1.22 mL, 2.5 equiv) was added dropwise. Upon completion of the addition, (E)-N-((6-fluoro-5-isopropylpyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (330 mg, 1.22 mmol, 1 equiv) in THF (2 mL) was added dropwise. The resulting mixture was stirred at −60° C. for 2 hours. The reaction mixture was then poured into ice water (30 mL) and stirred for 2 minutes. The resulting biphasic mixture was then extracted with ethyl acetate (3 × 20 mL). The combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give N-((3-(1H-pyrazol-5-yl)phenyl)(6-fluoro-5-isopropylpyridin-2-yl)methyl)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 22 H 26Calculated for FN4OS: 415.2; measured 415.2.

[0210] Step b: To a solution of N-((3-(1H-pyrazol-5-yl)phenyl)(6-fluoro-5-isopropylpyridin-2-yl)methyl)-2-methylpropane-2-sulfinamide (410 mg, 989 umol, 1 equiv.) in dioxane (2 mL) at 15° C., HCl / dioxane (4 mL) was added dropwise. The resulting mixture was stirred at 15° C. for 2 hours. The reaction mixture was then concentrated under reduced pressure to give (3-(1H-pyrazol-5-yl)phenyl)(6-fluoro-5-isopropylpyridin-2-yl)methanaminium chloride. LC-MS (ESI): m / z: [M+H] + C 18 H 19 Calculated for FN4: 311.2; measured 311.2.

[0211] Intermediate A-5: Synthesis of (S)-(3-fluoro-4-isopropylphenyl)(phenyl)methanaminium chloride [ka] Step a: To a mixture of 4-bromo-3-fluoro-benzaldehyde (200 g, 985 mmol, 1.00 equiv.) and 2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (215 g, 1.28 mol, 1.30 equiv.) in toluene (3.70 L) and HO (410 mL) at 25 °C, Pd(dppf)Cl (36.0 g, 49.3 mmol, 0.05 equiv.) and KPO (418 g, 1.97 mol, 2.00 equiv.) were added under N under N. The mixture was warmed to 90 °C and stirred for 12 h. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give 3-fluoro-4-isopropenyl-benzaldehyde. The compound was carried on to the next step without further characterization.

[0212] Step b: To a solution of 3-fluoro-4-isopropenyl-benzaldehyde (124 g, 755 mmol, 1.00 equiv) in EtOAc (1.20 L) was added Pd / C (85.0 g, 10 wt%) under N. The suspension was degassed and purged with H several times. The mixture was stirred under H (15 psi) at 25 °C for 1 h. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give 3-fluoro-4-isopropyl-benzaldehyde. The compound was carried on to the next step without further characterization.

[0213] Step c: To a mixture of 3-fluoro-4-isopropyl-benzaldehyde (80.0 g, 481 mmol, 1.00 equiv.) and (R)-2-methylpropane-2-sulfinamide (64.2 g, 523 mmol, 1.10 equiv.) in DCM (450 mL) at 25 °C, Cs2CO3 (173 g, 530 mmol, 1.10 equiv.) was added. The mixture was warmed to 40 °C and stirred for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to give (R,E)-N-(3-fluoro-4-isopropylbenzylidene)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 14 H 20 Calculated for FNOS: 270.1; measured value 270.0.

[0214] Step d: To a solution of (R,E)-N-(3-fluoro-4-isopropylbenzylidene)-2-methylpropane-2-sulfinamide (30.0 g, 111 mmol, 1.00 equiv.) in THF (400 mL) at −65° C., a solution of phenylmagnesium bromide (3 M in EtO, 55.7 mL, 1.50 equiv.) was added dropwise over 30 min under N. The reaction mixture was stirred at −65° C. for 6 h, then warmed to 25° C. and stirred for an additional 6 h. The reaction mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EtOAc (3 × 30 mL). The combined organic extracts were washed with water (3 × 30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (R)-N-((S)-(3-fluoro-4-isopropylphenyl)(phenyl)methyl)-2-methylpropane-2-sulfinamide, which was carried on to the next step without further characterization.

[0215] Step e: To a mixture of (R)-N-((S)-(3-fluoro-4-isopropylphenyl)(phenyl)methyl)-2-methylpropane-2-sulfinamide (35.0 g, 101 mmol, 1.00 equiv.) in EtOAc (300 mL) at 25° C., HCl / EtOAc (4 M, 50.4 mL, 2.00 equiv.) was added, and the mixture was stirred for 2 h. The reaction mixture was filtered, and the resulting solid was set aside. The filtrate was concentrated under reduced pressure, and the resulting residue was combined with the previously obtained solid. The mixture was dissolved in MTBE (200 mL), filtered, and the filtrate was concentrated under reduced pressure to give (S)-(3-fluoro-4-isopropylphenyl)(phenyl)methanaminium chloride.

[0216] Intermediate A-6: Synthesis of (S)-(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methanaminium chloride [ka] Step a: In four parallel reactions, 6-fluoropyridin-2-amine (125 g, 1.11 mol, 1 equiv) in MeCN (1.2 L) at 0 °C was treated with NBS (209 g, 1.17 mmol, 1.05 equiv) in MeCN (1.2 L) under N2. The reaction mixture was stirred at 20 °C for 2 h. The four parallel reactions were combined and the resulting mixture was concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give 5-bromo-6-fluoropyridin-2-amine. LC-MS (ESI): m / z: [M+H] + Calculated for C5H4BrFN2: 190.9; found 191.0.

[0217] Step b: To a mixture of 5-bromo-6-fluoropyridin-2-amine (200 g, 1.04 mol, 1 equiv.) and cyclopropylboronic acid (226 g, 2.63 mol, 2.5 equiv.) in 1,4-dioxane (2 L) and HO (200 mL), KPO (666 g, 3.14 mol, 3 equiv.), PCy (58.6 g, 209 mmol, 0.2 equiv.), and Pd(OAc) (11.7 g, 52.3 mmol, 0.05 equiv.) were added under N. The system was then degassed and flushed with nitrogen three times. The reaction mixture was warmed to 100 °C and stirred for 12 h. The reaction mixture was then cooled to room temperature and filtered through Celite. The resulting filtrate was diluted with HO (2 L) and extracted with EtOAc (3 × 500 mL). The combined organic extracts were washed with brine (2 x 300 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by column chromatography to give 5-cyclopropyl-6-fluoropyridin-2-amine. LC-MS (ESI): m / z: [M+H] + Calculated for C8H9FN2: 153.1; found 153.0.

[0218] Step c: To a mixture of 5-cyclopropyl-6-fluoropyridin-2-amine (120 g, 788 mmol, 1 equiv.) in dibromomethane (564 mL) was added isopentyl nitrite (110 g, 946 mmol, 127 mL, 1.2 equiv.) under N. To the resulting mixture was added CuBr (211 g, 946 mmol, 44.3 mL, 1.2 equiv.) over 0.5 h. The final mixture was then degassed and flushed with nitrogen three times and then stirred at 20 °C for 16 h. The reaction mixture was then filtered, and the filtrate was diluted with HO (500 mL) and extracted with EtOAc (3 × 300 mL). The combined organic extracts were washed with brine (300 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give 6-bromo-3-cyclopropyl-2-fluoropyridine. LC-MS(ESI):m / z:[M+H] + Calculated for C8H7BrFN: 216.0; found 216.1.

[0219] Step d: To a mixture of 6-bromo-3-cyclopropyl-2-fluoropyridine (90 g, 416 mmol, 1 equiv.) and trifluoro(vinyl)-λ-borane, potassium salt (83.7 g, 624 mmol, 1.5 equiv.) in i-PrOH (900 mL) at 20 °C, TEA (126 g, 1.25 mol, 3 equiv.) and Pd(dppf)Cl·DCM (17 g, 20.8 mmol, 0.05 equiv.) were added under N. The resulting mixture was degassed and flushed with nitrogen three times. The reaction mixture was then warmed to 100 °C and stirred for 2 h. The reaction mixture was then cooled to room temperature and filtered. The filtrate was diluted with HO (500 mL) and extracted with EtOAc (3 × 300 mL). The combined organic extracts were washed with brine (300 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude residue was then purified by column chromatography to give 3-cyclopropyl-2-fluoro-6-vinylpyridine. LC-MS (ESI): m / z: [M+H] + C 10 H 10 Calculated for FN: 164.1; measured 164.1.

[0220] Step e: To a mixture of 3-cyclopropyl-2-fluoro-6-vinylpyridine (47 g, 288 mmol, 1 equiv.) in THF (800 mL) and HO (160 mL) at 20 °C, NaIO (246 g, 1.15 mol, 4 equiv.) and KOsO·2HO (2.12 g, 5.76 mmol, 0.02 equiv.) were added under N. The resulting mixture was degassed and flushed with nitrogen three times and then stirred for 2 h. The reaction mixture was then filtered, and the filtrate was diluted with HO (500 mL) and extracted with EtOAc (3 × 300 mL). The combined organic extracts were washed with brine (300 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography to give 5-cyclopropyl-6-fluoropicolinaldehyde. LC-MS(ESI):m / z:[M+H] + Calculated for C9H8FNO: 166.1; found 166.2.

[0221] Step f: To a mixture of 5-cyclopropyl-6-fluoropicolinaldehyde (38 g, 230 mmol, 1 equiv.) and (S)-2-methylpropane-2-sulfinamide (30.6 g, 253 mmol, 1.1 equiv.) in DCM (200 mL) at 20 °C, CsCO (82.4 g, 253 mmol, 1.1 equiv.) was added under N. The system was then degassed and filled with nitrogen three times. The resulting mixture was then warmed to 40 °C and stirred for 12 h. The reaction solution was then diluted with HO (300 mL) and extracted with DCM (3 × 200 mL). The combined organic extracts were washed with brine (200 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was then purified by column chromatography to give (S,E)-N-((5-cyclopropyl-6-fluoropyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 13 H 17 Calculated for FN2OS: 269.1; measured 269.2.

[0222] Step g: To a solution of (S,E)—N-((5-cyclopropyl-6-fluoropyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (58 g, 216 mmol, 1 equiv.) in anhydrous DCM (600 mL) at −70° C. under nitrogen was added PhMgBr (3 M in EtO, 93.6 mL, 281 mmol, 1.3 equiv.). The resulting reaction mixture was stirred at −70° C. for 1 h. The reaction mixture was then quenched with saturated aqueous NH4Cl (500 mL), warmed to room temperature, and extracted with EtOAc (3×200 mL). The combined organic extracts were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (S)-N-((S)-(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methyl)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 19 H 23 Calculated for FN2OS: 347.2; measured 347.3.

[0223] Step h: To a solution of (S)-N-((S)-(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methyl)-2-methylpropane-2-sulfinamide (74 g, 213 mmol, 1 equiv.) in EtOAc (100 mL) at 0 °C was added HCl / EtOAc (4 M, 740 mL, 2940 mmol, 13.8 equiv.) under N2. The resulting mixture was then warmed to 20 °C and stirred for 1 h. The reaction mixture was then concentrated under reduced pressure, and the resulting crude residue was triturated with MTBE (500 mL). The resulting solid was collected by filtration and dried under reduced pressure to give (S)-(5-cyclopropyl-6-fluoropyridin-2-yl)(phenyl)methanaminium chloride. LC-MS (ESI): m / z: [M+H] + C 15 H 15 Calculated for FN2: 243.1; measured 243.2.

[0224] Intermediate A-7: Synthesis of (S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(1-methyl-1H-pyrazol-5-yl)phenyl)methanaminium chloride [ka] Step a: In two parallel reactions, a solution of 6-bromo-2-fluoro-3-isopropylpyridine (5 g, 22.9 mmol, 1 equiv) in THF (25 mL) was cooled to 0 °C under N. To this solution was added i-PrMgCl·LiCl (1.3 M in THF, 26.5 mL, 1.5 equiv) dropwise. The reaction mixture was then warmed to 25 °C and stirred for 2 h. At this time, the reaction mixture was cooled to 0 °C and DMF (5.3 mL, 68.8 mmol, 3 equiv) was added dropwise. After the addition was complete, the reaction mixture was warmed to 25 °C and stirred for 1 h. At this time, the two separate reactions were combined for workup. The combined reaction mixture was quenched with NH4Cl (70 mL), and the resulting biphasic mixture was extracted with ethyl acetate (2 × 50 mL). The combined organic extracts were washed with brine (2 x 50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude residue obtained was purified by column chromatography to give 6-fluoro-5-isopropylpicolinaldehyde. LC-MS (ESI): m / z: [M+H] + C9H 10 Calculated FNO: 168.1; measured 168.2.

[0225] Step b: In two parallel reactions, CsCO (3.64 g, 11.2 mmol, 1.1 equiv.) was added to a mixture of 6-fluoro-5-isopropylpicolinaldehyde (1.70 g, 10.1 mmol, 1 equiv.) and (S)-2-methylpropane-2-sulfinamide (1.36 g, 11.2 mmol, 1.1 equiv.) in DCM (20 mL). The resulting mixture was warmed to 40 °C under N and stirred for 2 h. At this time, the two parallel reactions were concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (S,E)-N-((6-fluoro-5-isopropylpyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 13 H 19Calculated for FN2OS: 271.1; measured 271.1.

[0226] Step c: To a solution of 1-bromo-3-iodo-benzene (5.22 g, 18.5 mmol, 2 equiv.) in THF (8 mL) at 0 °C was added i-PrMgCl·LiCl (1.3 M in THF, 10 mL, 1.4 equiv.) dropwise under N2. The resulting mixture was warmed to 25 °C and stirred for 2 h. At this time, the reaction mixture was cooled to −65 °C, and a solution of (S,E)-N-((6-fluoro-5-isopropylpyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (2.5 g, 9.25 mmol, 1 equiv.) in DCM (30 mL) was added dropwise. The resulting mixture was stirred at −65 °C for 3 h under N2. The reaction mixture was then quenched with NHCl (70 mL), and the resulting biphasic mixture was extracted with ethyl acetate (2 × 100 mL). The combined organic extracts were washed with brine (2 x 50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography. This material was further purified by preparative HPLC (column: Phenomenex Titank C18) to give (S)-N-((S)-(3-bromophenyl)(6-fluoro-5-isopropylpyridin-2-yl)methyl)-2-methylpropane-2-sulfinamide as the second eluting isomer. LC-MS (ESI): m / z: [M+H] + C 19 H 24 Calculated for BrFN2OS: 427.1; found 427.0.

[0227] Step d: To a mixture of (S)-N-((S)-(3-bromophenyl)(6-fluoro-5-isopropylpyridin-2-yl)methyl)-2-methylpropane-2-sulfinamide (550 mg, 1.29 mmol, 1 equiv.) and (1-methyl-1H-pyrazol-5-yl)boronic acid (324 mg, 2.57 mmol, 2 equiv.) in dioxane (2.5 mL) and HO (2.5 mL), KCO (534 mg, 3.86 mmol, 3 equiv.) and Pd(dppf)Cl·CHCl (105 mg, 129 μmol, 0.1 equiv.) were added. The resulting mixture was then warmed to 90 °C and stirred for 2 h. The reaction mixture was then quenched with HO (10 mL) and extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were washed with brine (20 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (S)-N-((S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(1-methyl-1H-pyrazol-5-yl)phenyl)methyl)-2-methylpropane-2-sulfinamide. LC-MS (ESI): m / z: [M+H] + C 23 H 29 Calculated for FN4OS: 429.2; measured 429.3.

[0228] Step e: To a solution of (S)-N-((S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(1-methyl-1H-pyrazol-5-yl)phenyl)methyl)-2-methylpropane-2-sulfinamide in ethyl acetate (1 mL) at 0° C., HCl / EtOAc (4 M, 15 mL) was added, and the resulting mixture was stirred at 0° C. for 1 h. The reaction was then concentrated under reduced pressure. The resulting crude residue was triturated with MTBE (10 mL) to give (S)-(6-fluoro-5-isopropylpyridin-2-yl)(3-(1-methyl-1H-pyrazol-5-yl)phenyl)methanaminium chloride. LC-MS (ESI): m / z: [M+H] + C 19 H 21 Calculated for FN4: 325.2; measured 325.2.

[0229] The following compounds in Table B-1 were synthesized using procedures similar to those for Intermediates A-1 to A-7 using the appropriate starting materials and reagents. [Table 12] [Table 13] [Table 14] [Table 15] [Table 16] [Table 17]

[0230] Intermediate A-9: Synthesis of (1R,2S)-2-((allyloxy)carbonyl)cyclopentane-1-carboxylic acid [ka] Step a: To a mixture of cis-tetrahydro-1H-cyclopenta[c]furan-1,3(3aH)-dione (6.25 g, 44.6 mmol, 1 equiv.) and (DHQD)2AQN (CAS: 176298-44-5, 3.06 g, 3.57 mmol, 0.08 equiv.) in toluene (1.7 L) was added allyl alcohol (25.9 g, 446 mmol, 30 mL, 10 equiv.) at −30° C. The resulting mixture was stirred at −30° C. for 170 h. The reaction was then quenched by the addition of aqueous HCl (1 M, 1 L), and the resulting biphasic mixture was extracted with EtOAc (2 × 1 L). The organic extracts were combined, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give (1R,2S)-2-((allyloxy)carbonyl)cyclopentane-1-carboxylic acid. Example S-1: [Table 18] [Table 19] [Table 20] [Table 21]

[0231] Example S-2: Synthesis of (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid (Compound 7) [ka] Step a: To a mixture of (R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methanaminium chloride (80.0 mg, 255 μmol, 1.00 equiv.), (1R,2S)-2-((allyloxy)carbonyl)cyclopentane-1-carboxylic acid (60.7 mg, 306 μmol, 1.20 equiv.), and N-methylimidazole (62.9 mg, 766 μmol, 3.00 equiv.) in CH3CN (5.00 mL) at -20 °C, chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (85.9 mg, 306 μmol, 1.20 equiv.) was added, and the resulting mixture was warmed to 0 °C and stirred for 1 h. The reaction mixture was then quenched by the addition of HO (5 mL) at 0 °C, and the resulting biphasic mixture was extracted with DCM (3 × 10 mL). The combined organic extracts were washed with brine (3 × 50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by column chromatography to give allyl (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylate. LC-MS (ESI): m / z: [M+H] + C 28 H 32 Calculated for FN3O4: 494.2; found 494.3.

[0232] Step b: To a solution of (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylate (130 mg, 263 μmol, 1.00 equiv) in DCM (5.00 mL) at −30 °C was added Pd(PPh) (91.3 mg, 79.0 μmol, 0.3 equiv) and barbituric acid (202 mg, 1.58 mmol, 6.00 equiv) under N. The resulting mixture was stirred at −30 °C for 1 h under a N atmosphere. The reaction mixture was then warmed to 0 °C and quenched by the addition of HO (5.0 mL), and the resulting biphasic mixture was extracted with DCM (3 × 10 mL). The combined organic extracts were washed with brine (10 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by preparative HPLC to give (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)methyl)carbamoyl)cyclopentane-1-carboxylic acid. LC-MS (ESI): m / z: [M+H] + C 25 H 28 Calculated for FN3O4: 454.2; found 454.2.

[0233] Example S-3: Synthesis of (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid (compound 23) [ka] Step a: To a solution of (3-fluoro-4-isopropylphenyl)(o-tolyl)methanaminium chloride (500 mg, 1.70 mmol, 1 equiv.) and cis-tetrahydro-1H-cyclopenta[c]furan-1,3(3aH)-dione (262 mg, 1.87 mmol, 1.1 equiv.) in THF (4 mL) was added DIPEA (659 mg, 5.11 mmol, 3 equiv.). The resulting mixture was stirred at 20 °C for 2 h. The reaction mixture was then diluted with HO (10 mL) and extracted with EtOAc (2 × 20 mL). The organic extract was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by preparative HPLC to give a mixture of diastereomers. This mixture was separated using chiral SFC (column: DAICEL CHIRALPAK AD) to give (1S,2R)-2-(((R)-(3-fluoro-4-isopropylphenyl)(o-tolyl)methyl)carbamoyl)cyclopentane-1-carboxylic acid as the second eluting isomer. LC-MS (ESI): m / z: [M+H] + C 24 H 28 Calculated for FNO3: 398.2; Measured: 398.2.

[0234] The following compounds in Table T-1 were synthesized using procedures similar to those of Examples S-2 and S-3 using the appropriate starting materials. [Table 22] [Table 23] [Table 24] [Table 25] [Table 26] [Table 27] [Table 28] [Table 29] [Table 30]

[0235] biological example Example B-1 The GYS1 coupling enzyme assay is a kinetic biochemical assay that indirectly quantifies the rate of glycogen synthesis by coupling the conversion of the GYS1 substrate UDP-glucose to UDP with downstream enzymatic reactions. UDP is released from UDP-glucose when a glucose monomer is attached to a growing glycogen chain by GYS1. The coupling assay then proceeds with pyruvate kinase utilizing UDP and phospho(enol)pyruvate (PEP) to form pyruvate. Lactate dehydrogenase then converts pyruvate and NADH to lactate and NAD+. The oxidation of NADH to NAD+ can be continuously measured using a plate reader by quantifying the decrease in NADH absorbance at 340 nm over time.

[0236] Compounds that inhibit the hGYS1 enzyme and the subsequent downstream conversion of NADH to NAD+ were tested using assay-ready plates (black, clear-bottom 384-well plates) in a final DMSO reaction volume of 2.5% DMSO. The assay buffer contained 50 mM Tris pH 7.5, 2 mM MgCl2, and 100 mM KCl. Fresh stocks of BSA at a final concentration of 0.02% and 1 mM TCEP were added before dividing the buffer into hGYS1 buffer and substrate buffer. Rabbit liver glycogen was added to the hGYS1 buffer to a final concentration of 0.2% glycogen. Glucose-6-phosphate was added to 1 mM, recombinant hGYS1 / GN1 protein was added to the substrate buffer at 50 nM, phosphoenolpyruvate (PEP) was added to 2 mM, UDP-glucose was added to 0.8 mM, NADH was added to 0.6 mM, and pyruvate kinase / lactate dehydrogenase was added to 20 units / mL. The reaction was initiated by mixing the hGYS1 buffer and substrate buffer in a 1:1 ratio. Both buffers were plated using a liquid dispensing device, with the hGYS1 buffer plated first, followed by the substrate buffer. The plate was briefly spun to remove air bubbles and immediately read at 340 nm absorbance in continuous mode at 1-minute intervals for 10 time points, for a total of 10 minutes. The slopes from these 10 time points were normalized to the positive and negative control wells. Duplicate % inhibition values ​​are then averaged and fitted to a Hill equation for dose response according to the Levenberg-Marquardt algorithm, with the maximum value of the Hill equation set to 100 and the minimum value set to 0.

[0237] IC of each compound 50 The results reported are shown in Table 3 below. Unless otherwise stated, IC 50 Values ​​are reported as the geometric mean of at least two assay runs on separate days. Each run represents the average of technical replicates, and each compound was assayed twice on the same plate. As shown in the table below, the compounds of the present invention are potent inhibitors of human GYS1.

[0238] Note that in Table 3, these compounds are referenced by the corresponding compound numbers in Table 1, which are also referenced in the synthetic examples. [Table 31] [Table 32] [Table 33]

[0239] Example B-2 The GYS1 cell-based assay is a bioluminescent assay that quantifies glucose resulting from glycogen digestion; the quantified glucose is an indirect measure of GYS1 glycogen synthesis. Newly synthesized glycogen is digested using glucoamylase, and the resulting glucose is quantified using Promega's Glucose-glo assay kit. Glucose-glo functions by coupling glucose oxidation and NADH production with an NADH-activated bioluminescence system. Glucose is oxidized by glucose dehydrogenase, which reduces NAD+ to NADH. NADH activates proluciferin reductase, which reduces the substrate to luciferin. Luciferin is detected in a luciferase reaction using Ultra-Glo rLuciferase and ATP; the luminescence produced is proportional to the glucose in the sample. Luminescence is measured as a single point read on a plate reader.

[0240] Compounds that inhibit the hGYS1 enzyme and subsequently inhibit glycogen synthesis in cells were tested using assay-ready plates (white, clear-bottom 384-well plates) in a final DMSO reaction volume of 1% DMSO. Compounds in the assay-ready plates were mixed with additive-free medium, except for 20 mM glucose, before adding to cells. HeLa cells were starved for 24 hours in additive-free medium, except for 1x Glutamax. Starved HeLa cells were plated at a 1:1 ratio to medium in the assay-ready plates and incubated for 24 hours at 37°C and 5% CO2. Cells were washed with 1x PBS buffer and lysed in lysis buffer containing 50% of the final volume of 1x PBS and 25% 0.3 N HCl in the well or reaction volume. Cells were incubated in lysis buffer for 10 minutes and quenched with the remaining 25% of the reaction volume, consisting of 450 mM Tris pH 8.0. The lysate was mixed with glucoamylase in a 1:1 ratio in 100 mM sodium acetate buffer at pH 5.3, and the mixture was incubated at 37°C for 1 hour. The digested lysate was mixed with Glucose-glo detection mix in a 1:1 ratio based on the vendor's recommendations (luciferase detection buffer, reductase, reductase substrate, glucose dehydrogenase, and NAD) in a readout plate (solid white 384-well plate) and incubated at room temperature for 1 hour. The plate was read using a plate reader with luminescence capabilities. The relative luminescence units (RLU) for each compound concentration were averaged and normalized to the average RLU of the positive and negative controls to obtain percentage inhibition. Normalized data versus concentration was plotted, and the half-maximal concentration (IC 50 To determine ), the Hill equation was fitted to the dose-response data using the Levenberg-Marquardt algorithm.

[0241] IC of each compound 50 The results reported are shown in Table 4 below. Unless otherwise stated, IC 50and values ​​are reported as the geometric mean of at least two assay runs on separate days. As shown in the table below, the compounds of the present invention are potent inhibitors of human GYS1. Unless otherwise specified, IC 50 Values ​​are reported as the geometric mean of at least two assay runs on separate days. Each run represents the average of technical replicates, and each compound was assayed twice on the same plate. [Table 34] [Table 35]

[0242] Example B-3 The GYS2 coupling enzyme assay is a kinetic biochemical assay that indirectly quantifies the rate of glycogen synthesis by coupling the conversion of the GYS2 substrate UDP-glucose to UDP with downstream enzymatic reactions. UDP is released from UDP-glucose when a glucose monomer is attached to the growing glycogen chain by GYS2. The coupling assay then proceeds with pyruvate kinase utilizing UDP and phospho(enol)pyruvate (PEP) to form pyruvate. Lactate dehydrogenase then converts pyruvate and NADH to lactate and NAD+. The oxidation of NADH to NAD+ can be continuously measured using a plate reader by quantifying the decrease in NADH absorbance at 340 nm over time.

[0243] Compounds that inhibit the hGYS2 enzyme and the subsequent downstream conversion of NADH to NAD+ were tested using assay-ready plates (black, clear-bottom 384-well plates) in a final DMSO reaction volume of 2.5% DMSO. The assay buffer contained 50 mM Tris pH 7.5, 2 mM MgCl2, and 100 mM KCl. Fresh stocks of BSA at a final concentration of 0.02% and 1 mM TCEP were added before dividing the buffer into hGYS2 buffer and substrate buffer. Rabbit liver glycogen was added to the hGYS2 buffer to a final concentration of 0.2% glycogen. Glucose-6-phosphate was added at 2 mM, recombinant hGYS2 / GN1 protein was added to the substrate buffer at 200 nM, phosphoenolpyruvate (PEP) was added at 2 mM, UDP-glucose was added at 2 mM, NADH was added at 0.6 mM, and pyruvate kinase / lactate dehydrogenase was added at 20 units / mL. The reaction was initiated by mixing the hGYS2 buffer and substrate buffer in a 1:1 ratio. Both buffers were plated using a liquid dispensing device, with the hGYS2 buffer plated first, followed by the substrate buffer. The plate was briefly spun to remove air bubbles and immediately read at 340 nm absorbance in continuous mode at 1-minute intervals for 10 time points, for a total of 10 minutes. The slopes from these 10 time points were normalized to the positive and negative control wells. Duplicate % inhibition values ​​are then averaged and fitted to a Hill equation for dose response according to the Levenberg-Marquardt algorithm, with the maximum value of the Hill equation set to 100 and the minimum value set to 0.

[0244] IC of each compound 50 The results reported are shown in Table 5 below. Unless otherwise stated, IC 50 and values ​​are reported as the geometric mean of at least two assay runs on separate days. As shown in the table below, the compounds of the present invention are not potent inhibitors of human GYS2. Unless otherwise stated, IC 50Values ​​are reported as the geometric mean of at least two assay runs on separate days. Each run represents the average of technical replicates, and each compound was assayed twice on the same plate. [Table 36]

[0245] Example B-4 Pompe disease is a glycogen storage disorder caused by mutations in the enzyme acid alpha-glucosidase, which leads to the pathological accumulation of glycogen. While glycogen can accumulate in virtually all tissues, the primary pathology affects skeletal and cardiac muscle. Inhibition of muscle glycogen synthesis could reduce pathological glycogen accumulation by acting as a substrate-reducing treatment. Savage et al. identified a predicted protein-truncating variant (PTV) in the PPP1R3A gene (a regulator of glycogen metabolism) in approximately 0.5% of Europeans, resulting in an approximately 65% ​​reduction in muscle glycogen (Savage et al., A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice. PLoS Medicine. 2008, the entire contents of which are incorporated herein by reference). PPP1R3A functions as a major activator of muscle glycogen synthase 1 (GYS1) by dephosphorylating the enzyme and maximizing its activity. Figure 1 shows the pathway by which PPP1R3A (loss-of-function) LoF leads to reduced muscle glycogen.

[0246] Large-scale biobanks allow for the investigation of the consequences of genetic variation on many health-related phenotypes. To assess the consequences of a predicted 65% loss of muscle glycogen, we conducted an association study comparing phenotypes between PPP1R3A PTV carriers and noncarriers in the UK Biobank. Genetic association studies were performed using REGENIE (Mbatchou, J., Barnard, L., Backman, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet 53, 1097-1103, 2021), adjusted for age, sex, and the first 10 principal components of ancestry. Quantitative traits were normalized using an inverse rank normal transformation.

[0247] For Figures 2A-2H, associations between PPP1R3A PTV and quantitative phenotypes are shown: left ventricular ejection fraction (LVEF) (%) (Figure 2A), left ventricular wall thickness (mm) (Figure 2B), exercise power (Watts) (Figure 2C), maximum heart rate (HR) exertion (bpm) (Figure 2D), PQ interval (ms) (Figure 2E), QRS duration (ms) (Figure 2F), QT interval (ms) (Figure 2G), and serum glucose (mmol / L) (Figure 2H). Phenotype values ​​are plotted by PPP1R3A dosage for UK Biobank participants. No associations between PPP1R3A PTV and quantitative phenotypes in UK Biobank were identified.

[0248] Table 6 below lists the P values ​​and number of participants (N) for the results shown in Figures 2A-2H. No associations were identified between PPP1R3A PTV and cardiac parameters, including left ventricular ejection fraction (p=0.871) and wall thickness (p=0.168). There was no evidence of changes in electrocardiographic cardiac conduction intervals or any muscle performance measures (n=49,616), including maximum heart rate (p=0.444) and maximum workload (p=0.100) during exercise testing. Furthermore, no changes were observed in serum glucose (p=0.71) or other members of a panel of approximately 170 serum metabolites. [Table 37]

[0249] No associations were observed between PPP1R3A PTVs and major health outcomes, as shown below in Table 7. In addition to the phenotypes in Table 7, no phenome-wide significant associations were observed between PPP1R3A PTVs and the proportion of any ICD10 code occurring 100 or more times in UK Biobank. [Table 38]

[0250] After conducting an extensive phenome-wide association study in the UK Biobank, no significant associations were found between important outcomes or phenotypes and loss of function of PPP1R3A. The results provided herein demonstrate that loss of function variants in the PPP1R3A gene are not associated with adverse health outcomes in a large biobank population. This suggests that partial reduction of muscle glycogen (approximately 65%) from birth is well tolerated, supporting the potential safety of pharmacological reduction of muscle glycogen.

[0251] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety to the same extent as if each was individually incorporated by reference.

[0252] While the present disclosure has been described in conjunction with the foregoing embodiments, it should be understood that the foregoing descriptions and examples are intended to illustrate, but not limit, the scope of the present disclosure. Other aspects, advantages, and modifications within the scope of the present disclosure will be apparent to those skilled in the art to which this disclosure pertains.

Claims

1. Formula (I): 【Chemical 1】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; Y １ and Y ２ are each CH, or Y １ and Y ２ One of the two is N, and Y １ and Y ２ the other of which is CH, X １ and X ２ are each independently H or halo; X ３ is H, C １～６ Alkyl, or C ３～１０ is cycloalkyl, and X ３ The above C ３～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; Q １ teeth, (i) C ６～１０ cycloalkyl, Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; (ii) C ６～２０ Aryl, wherein Q １ The above C ６～２０ Aryl is one or more R ｂ and each R ｂ are independently １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R ｂ The 5- to 20-membered heteroaryl may have one or more C １～６ optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, wherein Q １ The 3- to 15-membered heterocyclyl may be one or more oxo or C １～６ optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, wherein Q １ The 5- to 20-membered heteroaryl may have one or more —NH ２ and when m is 1, Q １ wherein said 5- to 20-membered heteroaryl contains at least one ring N; However, X ３ If is H, then Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl, and R ａ is H, halo, —OH, or —NH—C(O)—C １～６ alkoxy, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

2. The compound of formula (I) 【Chemistry 2】 2. The compound of claim 1 having the stereochemical configuration: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

3. 3. The compound of claim 1 or 2, wherein m is 0 and n is 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

4. 3. The compound of claim 1 or 2, wherein m is 1 and n is 0, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

5. Y １ and Y ２ and each is CH, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

6. of formula (I) 【Chemistry 3】 but, 【Chemistry 4】 6. The compound of any one of claims 1 to 5, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

7. Y １ and Y ２ One of the two is N, and Y １ and Y ２ and the other is CH, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

8. of formula (I) 【Chemistry 5】 but, 【Chemistry 6】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

9. X １ and X ２ is each independently H or F, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

10. X ３ But H, C １～３ Alkyl, or C ３～６ is cycloalkyl, and X ３ The above C ３～６ Cycloalkyl is one or more C １～３ 10. A compound according to any one of claims 1 to 5, 7, or 9, optionally substituted with alkyl, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

11. Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ 11. A compound according to any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted with alkyl.

12. Q １ but 【Chemistry 7】 12. The compound of any one of claims 1 to 11, wherein:

13. Q １ is C ６～２０ aryl, and Q １ The above C ６～２０ The aryl is one or more R ｂ and each R ｂ But independently, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, and R ｂ wherein said 5- to 20-membered heteroaryl is one or more C １～６ 11. A compound according to any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted with alkyl.

14. Q １ is phenyl, and Q １ wherein the phenyl is one or more R ｂ and each R ｂ are independently —CH ３ , -OCH ３ , -NH-C(O)-NH ２ , —NH—C(O)—(3- to 6-membered heterocyclyl), or 5- to 10-membered heteroaryl, and R ｂ wherein said 5- to 10-membered heteroaryl is one or more —CH ３ 14. The compound of any one of claims 1 to 10, or 13, optionally substituted with:

15. Q １ but, 【Chemistry 8】 15. The compound of any one of claims 1 to 10, 13, or 14, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

16. Q １ is a 3- to 15-membered heterocyclyl; １ wherein the 3- to 15-membered heterocyclyl is one or more oxo or C １～６ 11. A compound according to any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted with alkyl.

17. Q １ but, 【Chemistry 9】 17. The compound of any one of claims 1 to 10, or 16, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

18. Q １ is a 5- to 10-membered heteroaryl; and Q １ wherein said 5- to 10-membered heteroaryl is one or more —NH ２ 11. The compound of any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally substituted with

19. Q １ but, 【Chemistry 10】 19. The compound of any one of claims 1 to 10, or 18, selected from the group consisting of: or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

20. R ａ is H, F, —OH, or —NH—C(O)—C １－４ 20. The compound of any one of claims 1 to 19, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is alkoxy.

21. R ａ is H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

22. R ａ is F, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

23. The compound has formula (IA): 【Chemistry 11】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: i.X ４～８ are each independently H, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl independently contains one or more C １～６ optionally substituted with alkyl; ii. X ６ But, X ４ or X ８ and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C １～６ optionally substituted with alkyl; X ５ , X ７ , and X ４ or X ８ and the other of each independently is H, oxo, or C. １～６ is alkyl, or 5-14 membered heteroaryl, wherein said 5-14 membered heteroaryl of ring A is one or more -NH ２ and when m is 1, said 5- to 14-membered heteroaryl of ring A contains at least one cyclic N, and X ５ , X ７ , and X ４ or X ８ and the other of each independently is H or a further —NH ２ or iii. X ７ But, X ５ or X ８ and the atoms to which they are attached form ring A, and ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C １～６ optionally substituted with alkyl; X ４ , X ６ , and X ５ or X ８ and the other of each independently is H, oxo, or C. １～６ is alkyl, or 5-14 membered heteroaryl, wherein said 5-14 membered heteroaryl of ring A is one or more -NH ２ and when m is 1, said 5- to 14-membered heteroaryl of ring A contains at least one cyclic N, and X ４ , X ６ , and X ５ or X ８ and the other of each independently represents H or —NH ２ 23. The compound of any one of claims 1 to 10, 13, 15, or 20 to 22, wherein:

24. X ４～８ One of them is C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)—(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl, wherein the 5- to 20-membered heteroaryl independently contains one or more C １～６ optionally substituted with alkyl; X ４～８ and the others of are each independently H, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

25. The compound has formula (IB): 【Chemistry 12】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

26. The compound has formula (IC): 【Chemistry 13】 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: Ring A is 3- to 9-membered heterocyclyl, wherein the 3- to 9-membered heterocyclyl of ring A is one or more oxo or C １～６ optionally substituted with alkyl, or 5-14 membered heteroaryl, wherein said 5-14 membered heteroaryl of ring A is one or more -NH ２ and when m is 1, said 5-14 membered heteroaryl of ring A contains at least one cyclic N, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

27. 2. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from the compounds in Table 1.

28. 28. A process for preparing a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising: (a) Formula (I-1): 【Chemistry 14】 or a salt thereof, wherein Y １ and Y ２ are each CH, or Y １ and Y ２ One of the two is N, and Y １ and Y ２ the other of which is CH, X １ and X ２ are each independently H or halo; X ３ is H, C １～６ Alkyl, or C ３～１０ is cycloalkyl, and X ３ The above C ３～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl, and Q １ teeth, (i) C ６～１０ cycloalkyl, Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; (ii) C ６～２０ Aryl, wherein Q １ The above C ６～２０ The aryl is one or more R ｂ and each R ｂ But independently, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R ｂ wherein said 5- to 20-membered heteroaryl is one or more C １～６ optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, wherein Q １ wherein the 3- to 15-membered heterocyclyl is one or more oxo or C １～６ optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, wherein Q １ wherein said 5- to 20-membered heteroaryl is one or more —NH ２ and when m is 1, Q １ wherein said 5- to 20-membered heteroaryl contains at least one cyclic N; However, X ３ If is H, then Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl in the presence of a coupling reagent to obtain a compound of formula (I-2): 【Chemistry 15】 (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; R ａ is H, halo, —OH, or —NH—C(O)—C １～６ is an alkoxy; and PG is a protecting group. to form a compound of formula (I-3): 【Chemistry 16】 (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; Y １ and Y ２ are each CH, or Y １ and Y ２ One of the two is N, and Y １ and Y ２ the other of which is CH, X １ and X ２ are each independently H or halo; X ３ is H, C １～６ Alkyl, or C ３～１０ is cycloalkyl, and X ３ The above C ３～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; Q １ teeth, (i) C ６～１０ cycloalkyl, Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; (ii) C ６～２０ Aryl, wherein Q １ The above C ６～２０ The aryl is one or more R ｂ and each R ｂ But independently, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R ｂ wherein said 5- to 20-membered heteroaryl is one or more C １～６ optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, wherein Q １ wherein the 3- to 15-membered heterocyclyl is one or more oxo or C １～６ optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, wherein Q １ wherein said 5- to 20-membered heteroaryl is one or more —NH ２ and when m is 1, Q １ wherein said 5- to 20-membered heteroaryl contains at least one cyclic N; However, X ３ If is H, then Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; R ａ is H, halo, —OH, or —NH—C(O)—C １～６ is alkoxy, and PG is a protecting group. followed by providing a compound of (b) contacting a compound of formula (I-3) with a deprotecting agent to provide a compound according to any one of claims 1 to 27.

29. 28. A process for preparing a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising: Formula (I-1): 【Chemistry 17】 or a salt thereof, wherein Y １ and Y ２ are each CH, or Y １ and Y ２ One of the two is N, and Y １ and Y ２ the other of which is CH, X １ and X ２ are each independently H or halo; X ３ is H, C １～６ Alkyl, or C ３～１０ is cycloalkyl, and X ３ The above C ３～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl, and Q １ teeth, (i) C ６～１０ cycloalkyl, Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; (ii) C ６～２０ Aryl, wherein Q １ The above C ６～２０ The aryl is one or more R ｂ and each R ｂ But independently, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R ｂ wherein said 5- to 20-membered heteroaryl is one or more C １～６ optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, wherein Q １ wherein the 3- to 15-membered heterocyclyl is one or more oxo or C １～６ optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, wherein Q １ wherein said 5- to 20-membered heteroaryl is one or more —NH ２ and when m is 1, Q １ wherein said 5- to 20-membered heteroaryl contains at least one cyclic N; However, X ３ If is H, then Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl in the presence of a coupling reagent to obtain a compound of formula (I-4): 【Chemistry 18】 (In the formula, m is 0 or 1, n is 0, 1, or 2, and m+n is an integer from 1 to 2; Y １ and Y ２ are each CH, or Y １ and Y ２ One of the two is N, and Y １ and Y ２ the other of which is CH, X １ and X ２ are each independently H or halo; X ３ is H, C １～６ Alkyl, or C ３～１０ is cycloalkyl, and X ３ The above C ３～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; Q １ teeth, (i) C ６～１０ cycloalkyl, Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl; (ii) C ６～２０ Aryl, wherein Q １ The above C ６～２０ The aryl is one or more R ｂ and each R ｂ But independently, C １～６ Alkyl, -C １～６ Alkoxy, —NH—C(O)—NH ２ , —NH—C(O)-(3- to 15-membered heterocyclyl), or 5- to 20-membered heteroaryl; R ｂ wherein said 5- to 20-membered heteroaryl is one or more C １～６ optionally substituted with alkyl; (iii) 3- to 15-membered heterocyclyl, wherein Q １ wherein the 3- to 15-membered heterocyclyl is one or more oxo or C １～６ optionally substituted with alkyl, or (iv) 5- to 20-membered heteroaryl, wherein Q １ wherein said 5- to 20-membered heteroaryl is one or more —NH ２ and when m is 1, Q １ wherein said 5- to 20-membered heteroaryl contains at least one cyclic N; However, X ３ If is H, then Q １ is C ６～１０ is cycloalkyl, and Q １ The above C ６～１０ Cycloalkyl is one or more C １～６ optionally substituted with alkyl, and R ａ is H, halo, —OH, or —NH—C(O)—C １～６ alkoxy) to provide a compound according to any one of claims 1 to 27.

30. 28. A pharmaceutical composition comprising: (i) a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; and (ii) one or more pharmaceutically acceptable excipients.

31. 31. A method of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to said individual a compound of any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 30.

32. 32. The method of claim 31, wherein the disease, disorder, or condition is a glycogen storage disorder (GSD).

33. 33. The method of claim 31 or 32, wherein the disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease.

34. 34. The method of any one of claims 31 to 33, wherein the disease, disorder, or condition is Pompe disease.

35. 32. The method of claim 31 , wherein the disease, disorder, or condition is cancer.

36. 36. The method of claim 31 or 35, wherein the disease, disorder, or condition is selected from the group consisting of Ewing's sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma (GRCC), breast cancer, non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML).

37. 32. The method of claim 31 , wherein the individual has a GAA mutation.

38. 38. The method of claim 37, wherein the GAA mutation is a loss-of-function mutation.

39. A kit comprising (i) a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, and (ii) instructions for use thereof in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

40. 40. The kit of claim 39, wherein the disease, disorder, or condition is a glycogen storage disorder (GSD).

41. 41. The kit of claim 39 or 40, wherein the disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease.

42. 42. The kit of any one of claims 39 to 41, wherein the disease, disorder, or condition is Pompe disease.

43. 43. The kit of claim 42, wherein the disease, disorder, or condition is cancer.

44. 44. The kit of claim 39 or 43, wherein the disease, disorder, or condition is selected from the group consisting of Ewing's sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma (GRCC), breast cancer, non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML).

45. 40. The kit of claim 39, wherein the individual has a GAA mutation.

46. 46. ​​The kit of claim 45, wherein the GAA mutation is a loss-of-function mutation.

47. 31. A method of modulating GYS1 in a cell, comprising exposing the cell to an effective amount of a composition comprising a compound of any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 30.

48. 31. A method of inhibiting GYS1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 30.

49. 31. A method of reducing tissue glycogen stores in an individual in need thereof, comprising administering to said individual an effective amount of a compound of any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 30.

50. 31. A method of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof, comprising subjecting said individual to glycogen substrate-reducing therapy, wherein said glycogen substrate-reducing therapy comprises administering to said individual an effective amount of a compound of any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 30.

51. 51. The method of claim 50, comprising subjecting the individual to glycogen substrate reduction therapy in combination with enzyme replacement therapy.

52. 52. The method of claim 51, wherein the enzyme replacement therapy is selected from the group consisting of alglucosidase alfa (human recombinant alpha glucosidase (human GAA)), Myozyme, and Lumizyme.

53. 53. The method of any one of claims 50 to 52, wherein the disease, disorder, or condition is a glycogen storage disorder (GSD).

54. 54. The method of any one of claims 50-53, wherein the disease, disorder, or condition is selected from the group consisting of Pompe disease, Cori disease (GSD III), adult polyglucosan body disease (APBD), and Lafora disease.

55. 55. The method of any one of claims 50 to 54, wherein the disease, disorder, or condition is Pompe disease.

56. 53. The method of any one of claims 50 to 52, wherein the disease, disorder, or condition is cancer.

57. 57. The method of any one of claims 50-52, or 56, wherein the disease, disorder, or condition is selected from the group consisting of Ewing's sarcoma (ES), clear cell renal cell carcinoma (ccRCC), glycogen-rich clear cell carcinoma (GRCC), breast cancer, non-small cell lung cancer (NSCLC), and acute myeloid leukemia (AML).

58. 53. The method of any one of claims 50 to 52, wherein the individual has a GAA mutation.

59. 59. The method of claim 58, wherein the GAA mutation comprises a loss-of-function mutation.

60. 50. The method of any one of claims 47 to 49, wherein the compound is selective for GYS1 over GYS2.

61. 61. The method of claim 60, wherein the compound is 500-fold or 1,000-fold or 1,500-fold or 1,700-fold selective for GYS1 over GYS2.

62. 62. The method of any one of claims 31-38 or 47-61, comprising reducing glycogen levels in skeletal muscle.

63. 31. A compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, for use in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

64. 31. A compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, for use in modulating GYS1 in a cell.

65. 31. A compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, for use in inhibiting GYS1 in a cell.

66. 31. A compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, for use in reducing tissue glycogen stores in an individual in need thereof.

67. 31. A compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, for use in glycogen substrate reduction therapy for the treatment of a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

68. 31. Use of a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for use in treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

69. 31. Use of a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for use in modulating GYS1 in a cell.

70. 31. Use of a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for use in inhibiting GYS1 in a cell.

71. 31. Use of a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for use in reducing tissue glycogen stores in an individual in need thereof.

72. 31. Use of a compound according to any one of claims 1 to 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition according to claim 30, in the manufacture of a medicament for use in glycogen substrate reduction therapy for the treatment of a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

Images